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Viral infections caused by HIV or influenza viruses have killed millions of people worldwide. The 
capability of these viruses to easily mutate their envelope glycoproteins is what makes treating 
both infections so hard. Currently available drugs against such viruses do combat the infections to 
some extent but are not the best long-term solutions; drug toxicity, drug resistance and viral 
persistence are just some of the issues that are yet to be overcome. In this work, the concept of 
polyvalency was used to design viral inhibitors and vaccines.  
Hemagglutinin is an envelope glycoprotein in the influenza virus, whose head region is highly 
prone to mutation but has certain conserved epitopes in the stalk region. These conserved epitopes 
in the stalk region are usually not easily accessible to the immune system, in a native influenza 
virus. For the first part of my thesis, a universal vaccine has been developed by controlling the 
antigen (hemagglutinin) presentation to the immune system to enhance the accessibility of the 
conserved epitopes in the stalk. Hemagglutinin-biotin was conjugated onto the surface of 
streptavidin coated nanotubes to yield conjugates with two different orientations of hemagglutinin; 
one with the stalk region facing outwards (proposed vaccine design, called head tagged-nanotube 
conjugates) and the other as the control with the head region facing outwards (tail tagged-nanotube 
conjugates). In preliminary in-vivo challenge experiments with a chimeric H5/1N1 virus, the head 
tagged-nanotube conjugates (proposed vaccine) showed better protection than controls. We have 
subsequently expressed biotinylated hemagglutinin using baculoviral infection of insect cells and 
have optimized the purification scheme by adding a size exclusion chromatography step after the 
affinity chromatography step. The resulting conjugates will be tested in-vivo against a 
homosubtypic (e.g., cH5/1N1) and heterosubtypic (H5 or H6 viruses) challenge in the future.   
xviii 
 
For the second part of my thesis, polyvalent influenza therapeutics have been designed based on 
‘hemagglutinin binding’ proteins that bind to conserved epitopes. Our goal was to characterize the 
efficacy of polyvalent versions of these hemagglutinin binding (HB) proteins relative to the 
monomers. We demonstrated that the dimers of both the HB proteins studied were more effective 
at inhibiting the binding of stalk-binding antibodies to hemagglutinin than the corresponding HB 
monomers.  
For the third part of my thesis, we designed polyvalent molecules that bind to multiple sites on 
CCR5 (C-C chemokine receptor, type 5). CCR5 plays a key role in HIV’s entry into host cells. We 
synthesized homodimeric, heterodimeric and multimeric versions of Leukotoxin E (LukE) (a 
CCR5-binding protein) and characterized their ability to inhibit the binding of a gp120-CD4 fusion 
protein (called FLSC) to CCR5+ 293T cells. Of these, Leukotoxin E – RoAb14 heterodimers, in 
which LukE and another CCR5-binding single chain variable fragment (scFv) version of the 
antibody, RoAb14, were separated by 75- and 100-amino acid linkers showed over 85% inhibition 
of FLSC binding at concentrations as low as 78nM, as compared to Leukotoxin E which showed 
50% inhibition at ~ 1.3µM. Polyvalent conjugates in which multiple copies of LukE were attached 
to polyglutamic acid scaffolds also showed an enhancement in avidity relative to LukE monomers. 




Polyvalency or multivalency involves the simultaneous binding of multiple copies of ligands to 
their corresponding receptors [1], [2]. Polyvalency exists abundantly in nature; some examples 
include viral attachment to host cells, antigen/antibody interactions, antigen presenting cell–T cell 
interactions, binding of bacterial toxins to host receptors, etc. [2]. The concept of polyvalency aids 
in reducing the half maximal inhibitory concentration (IC50) of ligands or molecules by several 
orders of magnitude, by increasing the avidity of the molecule/ligand for its receptors. Half 
maximal inhibitory concentration (IC50) is defined as the concentration of inhibitor at which the 
maximum response is reduced by 50%. We have extensively used the concept of polyvalency in 
our research in the design and synthesis of various inhibitors and vaccines [3]–[10]. 
The goal of this work is to use polyvalency to combat HIV and influenza viruses. Viral diseases 
caused by influenza or HIV have wreaked havoc in the lives of many over the last century or so. 
Influenza has reached pandemic proportions multiple times in the past century and has claimed 
over 30 million lives [11]. HIV has killed about 39 million people since the beginning of the 
epidemic (early 80s) by eventually destroying the body's capability to fight off infections. 
Currently about 35 million people are infected with HIV [12]. Many previous attempts to counter 
both HIV and influenza infections face steep challenges, some of which include drug toxicity (e.g. 
certain HIV therapeutics) or the ability of the viruses to mutate its envelope proteins, to evade 
detection by the hosts’ immune system. Simply using an inactivated or attenuated virus is far from 
being the solution; by the time the immune system bolsters a response against such a threat, the 
virus would have already mutated its surface glycoproteins, thereby rendering the immune 




1.1. Influenza Virus 
The envelope of the influenza virus has two key glycoproteins: hemagglutinin (HA – a mutation-
prone protein that helps the virus to attach itself to host cells) and neuraminidase (NA - an enzyme 
that helps the budding virions to be released from the host cell). The host receptor for HA is an α-














Figure 1: Mechanism of host cell entry of Influenza; figure adapted from Lucas et al. 
2010  [66] 
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HA0 is the pre-cleaved form of HA, before cleavage by host cell proteases into HA1 (primarily 
contains the head region) and HA2 (contains stalk region). Once the virus has latched onto the 
sialic acid receptors on the host cell, it is endocytosed into the cell. As the endosomal vesicle 
moves towards the host nucleus, the pH within the vesicle drops. Once the pH reaches ~ 5.0, the 
HA undergoes a conformational rearrangement, which results in the exposure of a highly-
conserved region, a hydrophobic fusion peptide at the N terminal region of HA2. This peptide 
inserts itself into the endosomal membrane, thereby helping release the viral RNA into the host 
cell’s cytoplasm for multiplication [14].  
Several antiviral molecules have been developed that target different stages of the viral replication 
cycle, some of which are FDA approved. Although these drugs have been shown to curb infection, 
a number of drug-resistant strains are appearing [15], [16]. Another issue is that these drugs can 
only be administered post-infection. Vaccines, on the other hand, offer an advantage: they help 
elicit antibodies against the virus even before the onset of infection. Currently available influenza 
vaccines primarily include live, attenuated (LAV) or (TIV - trivalent influenza viruses) inactivated 
viruses, whose composition is based on those strains that are currently circulating both nationally 
and internationally, past trends, and how well the current strains work against newly identified 
viruses. The data on virus strains that is collected for vaccine design needs to be regularly updated 
so that we are prepared for the next flu season [17]. The problem with the current approach is that 
there is no guarantee that the vaccine will boost an immune response against the seasonal influenza 
viruses that end up being prevalent the next flu season. This leaves room for improvement in the 
design of a more “universal” vaccine [18]. 
Based on similarities and differences in their sequence and structure, HA is classified into different 
subtypes, labelled H1 through H17, and more broadly into two phylogenetically different groups: 
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group 1 (includes HA subtypes 1, 2, 5, 6, 8, 9, 11, 12, 13, 16, 17) and group 2 (includes HA 
subtypes 3, 4, 7, 10, 14, 15) [19]. Even if the currently available vaccine successfully inhibits 
infection, the virus can easily mutate the immunodominant surface epitopes of HA so as to escape 
detection by the hosts’ immune system (or undergo ‘antigenic drift’) [18]. The antibodies 
generated against the annual vaccines are primarily against the head region of HA and work by 
preventing the binding of the virus to the host cell and egress of the budding virion from the host 
cell [20]. So, once the exposed residues on the head are mutated, the anti-head antibodies generated 
against the previous set of epitopes are rendered ineffective. 
Even though the HA head is highly prone to mutation, there are some conserved residues in the 
stalk region. These conserved residues consist mainly of the N terminal region of HA2 (fusion 
peptide) and the hydrophobic groove region that surrounds it. The virus is unable to mutate these 
conserved regions as they are key residues required for successful membrane fusion. Broadly 
neutralizing antibodies (bnAbs) have been generated against such conserved epitopes of the 
influenza viral proteins. They hamper viral replication by preventing successful viral-host 
membrane fusion [20]. BnAbs have been shown to exhibit cross-reactivity to different HA 
subtypes within a group [21]. Wu et al. have studied the protective nature of bnAbs being injected 
in-vivo right after the onset of infection; they have shown that the bnAbs boost passive immunity 
[22]. In addition to the use of recombinant broadly neutralizing antibodies for prophylaxis, the 
design of antigens that generate broadly neutralizing antibodies is a promising avenue for 
combating influenza [23]–[26]. 
In this work, the conserved stalk region of HA is targeted for influenza vaccine and therapeutic 
design. Currently, two projects are being pursued in the area of influenza vaccine/inhibitor design 
and production. Firstly, a universal carbon nanotube-based influenza vaccine was synthesized to 
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study the effect of the presentation of PR8/H1 HA displayed to the immune system. The HA was 
conjugated to single walled carbon nanotubes (SWNT) in two orientations: one with the HA head 
towards the solution (away from the nanoscale support) with the tail attached to the nanotubes 
(NTs) and the other, with the stalk towards the solution. The vaccine was tested in-vivo for broadly 
neutralizing activity by our collaborators at the Icahn School of Medicine at Mount Sinai which 
gave some very encouraging preliminary results.  
Secondly, multivalent conjugates of hemagglutinin binding proteins were designed and 
synthesized; these will be tested as a therapeutic against influenza. Monomeric ‘hemagglutinin 
binding (HB) proteins’ were designed by David Baker’s group at the University of Washington. 
The HB proteins were designed to bind to the conserved HA stem-binding sites utilized by other 
bnAbs such as CR6261 and F10 [27], [28]. Once the overlapping ‘hotspot’ binding sites were 
mapped out, they searched the protein data bank for proteins that would have a shape 
complementary to the binding sites in the hydrophobic groove on HA. They modified the selected 
scaffold so as to incorporate the sites that would interact with the hotspot binding sites [27], [28]. 
We designed polyvalent copies of these HB molecules; on peptide-linker-based scaffolds of 
appropriate linker length, with the aim of making anti-influenza therapeutics with an activity 
significantly greater than that of the monomer alone. 
 
1.2. HIV 
HIV, like influenza, first binds to host cell receptors using its surface glycoproteins (gp120) before 
entry. HIV uses CD4 as the primary receptor and CCR5 or CXCR4 as the co-receptor for entering 
host cells (CD4+ T cells, macrophages and dendritic cells) [29]. Based on the type of co-receptor 
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used by the virus, it is called either an R5 (uses CCR5 as co-receptor) or an X4 virus (prefers 
CXCR4). The envelope glycoproteins consists of gp160 ‘precursor’ units which consists of gp120 
(required for the initial viral-cell binding) and gp41 (contains the viral fusion peptide) [30]. The 
two subunits are cleaved by host proteases. First, the gp120 binds to CD4 receptor on host cells 
[30]–[32]. This binding triggers a conformational change in gp120 and is followed by the binding 
of gp120 to the co-receptors CCR5 or CXCR4. Further conformational changes in the viral 
envelope allows for the insertion of the fusion peptide in gp41 into the host membrane, resulting 








HIV has one of the highest mutation rates among viruses which prevents it from being detected 
and easily eliminated by the immune system. Other than using antigenic drift to evade the immune 
system, the virus can also switch its tropism. R5 tropism is dominant in the ‘acute and 
asymptomatic’ initial phases of infection, but the virus has the capacity to mutate to X4 tropism as 
the disease progresses (called viral shift) [29]. So, if CCR5 was targeted in the initial phase of the 
disease, there are better chances of preventing disease progression than using CCR5 inhibitors in 
Figure 2: Mechanism of host cell entry of HIV; figure adapted from Wilen et al. 2012 [32] 
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the advanced stages. In the latter stages, the virus gets a selective advantage to switch to using the 
CXCR4 receptor [33].  
Currently available treatments involve combinational therapy (called HAART or highly active 
retroviral therapy) which do show marked improvement in preventing disease progression [30]. It 
involves using a combination of agents that target different receptors or steps of infection, some 
of which include nucleoside reverse transcriptase inhibitors, fusion inhibitors, protease inhibitors 
and CCR5 inhibitors/entry inhibitors. However there are serious side effects to the available drugs 
such as toxic side effects, high cost, difficulties in adhering to treatment and drug resistance [30]. 
Targeting the CCR5 receptor for anti-HIV therapy does have its advantages. Firstly, CCR5 is 
amenable to drug development, as it is not prone to antigenic drift as are the HIV envelope 
glycoproteins [30]. Secondly, the CCR5 receptor is an ‘expendable’ receptor; it has been shown 
that individuals having a ‘CCR5 delta32 mutation’ or the deletion of a set of 32 base pairs in the 
sequence of the extracellular loop 2 in their CCR5 (which causes a misfolded CCR5 to be 
expressed on the cell surface) are either resistant to HIV infection or the disease progresses 
extremely slowly in such individuals [34][35].    
Leukotoxin E (LukE) is a protein derived from staphylococcal aureus, and from the name itself, 
suggests that it is toxic to leukocytes. LukE by itself is harmless to cells, but when paired with 
Leukotoxin D (LukD), can cause cell death through pore formation [36]. LukE has recently been 
shown to bind to the HIV co-receptor CCR5 [37]. Our goal was to design polyvalent conjugates 
presenting multiple copies of LukE alone, as well as conjugates presenting both LukE and other 
proteins (e.g., scFvs) that bind to alternate sites  on CCR5 (as shown in the schematic in figure 3), 













1.3 Research Objectives:  
I. To develop a novel universal influenza vaccine by controlling antigen 
presentation and to characterize its structure and activity in-vivo. 
II. To synthesize multivalent conjugates of hemagglutinin-binding proteins and 
characterize their activity in-vitro.  
III. To synthesize multivalent conjugates that bind to the HIV co-receptor CCR5 





Figure 3: Schematic of a heterodimeric CCR5 binder; CCR5 schematic adapted from 
Lopalco et al., 2010 [67]  
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2. Universal Influenza Vaccine 
2.1. Introduction 
The goal of this project was to develop a strategy for designing a novel influenza vaccine with 
orientation-controlled antigen presentation that will elicit a broadly neutralizing response in-vivo, 
and provide complete protection against other group 1 viral challenges such as viruses with HA 
subtypes H5 and H6. Broadly neutralizing antibodies target certain conserved epitopes on HA, 
which the virus requires for replication and prevents infection by inhibiting membrane fusion [20].  
Here, the PR8/H1 HA (hemagglutinin subtype H1 of the Puerto Rico strain 8) was presented in 
two orientations; one where the head of HA was towards the solution (away from the nanoscale 
support) and the tail was the point of attachment to the nanotube (NT) scaffold, and the other where 
the tail was towards the solution. The viral envelope has a dense packing of proteins (HA and NA) 
which might restrict the accessibility of the conserved epitopes in the stalk region to the immune 
system. We hypothesized that by modifying the orientation of HA, we would enhance the 
accessibility and recognition of these conserved epitopes. Therefore, we expected a “broader” 
neutralizing response from the conjugates with the HA stalk towards the solution. The vaccine was 
designed as follows: Raw single walled carbon nanotubes were treated with a concentrated acid 
mixture for both length reduction and formation of –COOH groups (to serve as reactive handles) 
on the cut surfaces of the tubes (called NT-COOH). This scaffold then had biotin-PEG2000-amine 
(BPA) chemically attached to the –COOH groups, using EDC-NHS [1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide – Sulfo-N-Hydroxysuccinimide] chemistry. Subsequently, 
the PEGylated nanotubes had streptavidin linked to the free biotin on the nanotube surface, to 
which HA (head-tag biotin or HA (HT)) or HA (tail-tag biotin or HA (TT)) was attached to give 
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two different conjugates; one with the tail towards the solution (away from the nanoscale support) 
or HT-NT and the other with the head towards the solution or TT-NT. The “tag” here refers to the 
insertion of an AviTag sequence either in the head or stalk region of hemagglutinin which acts as 













The expression of the antigen, hemagglutinin, was carried out using insect cell culture [39]. Insect 
cells offers the advantage of producing correctly folded and glycosylated protein. Expression in 
insect cells using the baculoviral system (pFastBac dual vector) gives high yields because it driven 
by the strong polyhedron promoter [39].  
Figure 4: Schematic illustrating the preparation of nanotube-hemagglutinin conjugates: 







For this, two different cell lines were used: 1. SF9 insect cells were used to both generate and scale 
up baculoviruses and 2. High Five insect cells were infected with baculoviruses for the expression 
of hemagglutinin. The hemagglutinin sequence was cloned into the pFastbac dual vector. The 
advantage was that this vector also allowed for the insertion of the sequence of BirA, a 
biotinylation enzyme. So, biotinylation would occur in-vivo at the AviTag sequence and HA would 
be secreted from the High Five cells. The hemagglutinin sequence lacked the native membrane-
anchoring domain and was followed by a C terminal trimerization and a hexa-His tag to aid in 
purification [39]. Since hemagglutinin tends to aggregate, a second round of purification using size 
exclusion chromatography was found to be necessary.  
 
2.2. Materials and Methods: 
2.2.1. Cutting and COOH functionalization of single walled carbon nanotubes (SWNT):  
i) 20mg of SWNT was weighed out (single walled carbon nanotubes, Unidym) and 
thoroughly dispersed into a concentrated acid mixture of sulfuric acid and nitric acid in 
the ratio of 3:1, where the total volume of acid was 4 ml acid/mg NT (i.e. 80mL).  
 
Note on safety measures:  
 Make sure you have personal protective equipment on (lab coat, gloves, and safety 
glasses).   
 Make sure that the weighing out of NTs is done in a fume hood.  
 Before weighing, remove any static on the container the NTs are to be weighed into 
(using a static gun); static disperses NT particles.  
 Clean up the area with a wet wipe after weighing the NTs.  
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 Wear a double layer of nitrile gloves while measuring out acids.  
 Try to avoid acid spills. In case of spill: (a) prevent it from entering drains (b) dilute 
it with water, and then neutralize with soda ash (sodium carbonate) or calcium 
oxide. Absorb neutralized spill with absorbent material and subsequently discard.  
ii) The nanotubes were sonicated in this acid mixture in an ice bath for a total of 21-22 
hours, to reduce their length from >1µm to 100-500nm. The ice in the sonicator bath 
was not allowed to completely melt and was replenished every 20-30 mins. 
Note:  The sonication should be done under a fume hood too, to minimize the formation and 
dispersion of aerosols. 
iii) After the acid-based NT cutting was complete, the reaction was quenched in 2L of 
chilled water. The COOH-NTs were filtered and resuspended in water. Repeated 
washes of NTs were performed till the filtrate was neutral in pH (~3-4 washes). 
iv) Finally, a concentrated solution of COOH-NTs was made and freeze dried to remove 
the water. This will help determine the NT yield.  
Note:  When NTs in the dried form require to be weighed, make sure it is done under the fume 
hood.  
Note: The SWNTs are purchased ‘raw’, and are cut with concentrated acid mixture of sulfuric 
and nitric acid. Acid “Cutting” is useful not just to size down the tubes but also to 
ensure that there are –COOH groups that are generated over the NT surface. The –
COOH group improves solubility and provides for a site for further functionalizing the 
NTs. 100-500nm would seem like an optimum size range for the NTs so that the 
antigen-coated NTs will be immunogenic enough, yet small enough (i.e. < 500nm) so 
as to not be easily engulfed and eliminated by the reticulo-endothelial system.  
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2.2.2. PEGylation of COOH-functionalized NTs:  
i) The NTs were resuspended in 25 mM MES (2-(N-morpholino)ethanesulfonic acid) 
buffer (pH 4.7) by making a 1 mg/mL solution and the solution was sonicated for 1-2 
hrs. The cut NTs should appear more soluble than the raw NTs.  
ii)  9.1 mg of sulfo-NHS (N-hydroxysulfosuccinimide) per mg of NT were added to the 
well-suspended NTs and sonicated for 5 min. 
iii) This was followed by the addition of 30.5 mg of (1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide) EDC per mg of NT and briefly sonicated. Then, a 
stir bar was added to the reaction mix and the reaction was vigorously stirred for ~20 
mins. This is the stage where the COOH groups are being activated for the attachment 
of biotin-PEG2000-amine groups.  
iv) In the meantime, a (>20mg/ml) concentrated solution of biotin-PEG2000-amine (20 
mg of BPA/mg of NT) was prepared in 100 mM phosphate buffer (pH 8.0), such that 
the volume of the BPA solution was the same as the NT solution in MES. This is so 
that the final pH is ~ 7.4-7.5 which would allow the reaction to go to completion. 
Increasing final pH is not recommended as this will cause the activated ester group to 
get quickly hydrolyzed and will prevent successful conjugation of BPA. The reaction 
was allowed to go to completion at RT for at least 3 hrs, or overnight at 4 °C.  
v) After reaction completion, the solution was given a 3 min spin at 1000xg to remove 
any larger aggregates that should be discarded.  The supernatant was carefully collected 
and washed to remove the unreacted BPA. This was done by spinning the solution at 
504,000xg (70,000rpm) using the 70Ti fixed angle rotor in an ultracentrifuge for an hr. 
or till the PEG-NTs pellet. The supernatant will contain the excess free BPA. The 
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supernatant was discarded carefully without disturbing the pellet and then the pellet 
was resuspended in fresh buffer (de-ionised water). The washes were repeated ~ 5 times 
so that the tubes are sufficiently washed.  
Note:   Make sure that the tubes that will be put in the ultracentrifuge rotors are precisely 
balanced upto +/- 10mg.  
vi)  The pellet was collected and resuspended in sterile water. The PEG-NTs can be stored 
at 4°C. To calculate the yield, the absorbance of a dilute solution was taken at 808 nm 
such that the absorbance scales linearly. The A808nm can be multiplied by the dilution 
factor and then divided by 0.0465mg l-1 cm-1 (Extinction coefficient for SWNT) for 
calculating the NT concentration [40].  
Note: Addition of biotin-PEG2000-amine helps in solubilizing the tubes further and the free 
biotin is useful for further conjugations. Besides, the toxicity of SWNTs has been 
shown to be dependent on their surface functionalization [40], [41]. PEG 
functionalization has shown to reduce the systemic toxicity of raw SWNTs [42]–[44]. 
The unreacted BPA must be separated from the NTs, else they will hamper with the 
conjugation steps ahead (i.e., the streptavidin addition stage).  
 
2.2.3. Conjugation of Streptavidin and HRP-biotin (test molecule): 
i) For 1 mg of biotin-PEG-NTs, large excesses (10 mg) of streptavidin was used to 
saturate the surface biotin on NTs. The 1 mg of biotin-PEG-nanotubes (at 200µg/ml) 
was mixed in small batches to a solution of streptavidin.  
Note: This mixing must not be done all at once to avoid crosslinking and 
aggregation/clumping of NTs. The ideal case is where the NT-PEG is well covered 
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with streptavidin, such that as many streptavidin sites are kept free as possible to allow 
maximum loading of HRP or HA.  
ii) The excess streptavidin was removed using a sucrose gradient of 4%, 10% and 30% 
sucrose which was spun at 175,000xg or 32000rpm (using a swinging bucket SW32Ti 
rotor) in an ultracentrifuge. The free streptavidin is held within the layers of the 
gradient, whereas the streptavidin coated NTs (strep-NT) form a pellet. This spin was 
allowed to go up to ~ 18 hrs so that the nanotube yield of NT-Strep is ~ 50-60%. The 
pellet was resuspended in 20 mM phosphate buffer (pH 7.4). The NT concentration can 
be calculated by taking the absorbance at 808 nm, which should be multiplied by the 
dilution factor and then divided by 0.0465mg l-1 cm-1 (Extinction coefficient for 
SWNT) [40]. 
iii) The strep-NT batch was split into two; to one batch (sample), biotinylated HRP 
(horseradish peroxidase – a test molecule here, to assess whether loading is possible) 
was mixed and to the other batch (control), a 2 mg/ml solution of biotin (at high excess 
of biotin, to block all the free sites of streptavidin) was added. The samples were kept 
on a rocking platform. After half an hour, biotinylated HRP was added to the second 
batch (control).  
iv) The sample and control batches were put through a sucrose gradient of 4%, 10% and 
30% sucrose and spun at 32000 rpm in an ultracentrifuge to remove the excess HRP-
biotin that can interfere with ELISAs for HRP. The NT-HRPs (sample) or the NT-BBs 
(biotin-blocked controls) were collected as a pellet. 
v) A TMB (3,3',5,5'-tetramethylbenzidine)-based ELISA was performed to assess loading 
of HRP onto NTs. For this ELISA, serial dilutions of both the sample and control were 
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loaded onto 96 well, clear flat bottom plates. Each well had no more than 100 µL of 
solution. Similarly, serial dilutions (of known mass/concentrations of HRP) of HRP-
biotin (for the standard curve) were also loaded onto the plate. To these wells, 100 µL 
of TMB solution was added and the absorbance was taken in a plate reader at 652nm. 
If HRP is present, it would give a blue coloration with TMB. The amount of HRP in 
the sample and control could be estimated from the plotted standard curve.  
 
2.2.4. TEM imaging with gold-biotin: 
A small fraction of the strep-NT samples was mixed with a solution of excess of gold 
biotin for TEM imaging. The imaging was done by my colleague, Chad Varner.  
 
2.2.5. Insect culture – Expression of hemagglutinin (antigen) [39]:  
All mutants of hemagglutinin (HT, TT, chimeras) were expressed using the following 
protocol:  
i) The baculoviral transfer plasmid was transformed into DH10Bac bacteria, which were 
midiprepped to yield bacmids.  
ii) SF9 cells were seeded in 6-well plates at a density of 2 x 105 cells/cm2. The bacmids 
were transfected into SF9 cells using Cellfectin II transfection reagent. For this, 2µg of 
the bacmid was diluted in serum free TNM-FH (with 1% Pen-Strep and 0.1% Pluronic 
F68) and mixed with 6µL of Cellfectin II. This was mixed and allowed to incubate for 
20 mins at room temperature.  
iii) The SF9 cells would have stuck to the bottom of the plate by this point. The supernatant 
of the seeded SF9 cells was removed and replaced with serum free TNM-FH. The 
17 
 
bacmid-reagent complex was added to this mix, and the plate was gently agitated for 5 
mins to facilitate mixing. The media was changed after 6 hours to full TNM-FH (10% 
FBS, 1% Pen-Strep and 0.1% Pluronic F68). The plate was incubated at 28ºC without 
CO2 for 6 days, and was occasionally checked to observe signs of infection (cells 
appear larger, enlarged nuclei, easily detach from the plate).   
iv) The media was harvested after 6 days (centrifugation at 2000xg, 5mins) and this 
contained the “P1” or the initial baculoviral stock. Such a stock of baculoviruses can 
be stored at 4ºC.  
v) This P1 stock was used to generate subsequent ‘amplified’ baculoviral stocks. The SF9 
cells were seeded in large T175 flasks at a density of 2 x 105 cells/cm2, by allowing 
them to settle for 20 min and subsequently replacing the media with TNM-FH with 
reduced serum (3% FBS). To this, 400 µL of P1 was added, and the flask was swirled 
to allow even distribution of the baculoviral inoculum. The flask was incubated at 28ºC 
without CO2 for 6 days, while occasionally checking for signs of infection.  
vi) The media was harvested by centrifugation at 2000xg for 5 min to yield the “P2” stock. 
The baculoviruses could be amplified as required and be used for expression.  
vii) Hemagglutinin expression: For a 50mL expression, ~ 25 – 30 million High Five cells 
were harvested from a pass (centrifugation at 100xg for 7 mins). These cells were 
resuspended with 4.5 mL of baculoviral stock of P3 and the cell suspension was 
incubated at room temperature for 20 min. In the meantime, 46 mL of fresh SFX 
medium was placed into a disposable 125 mL Erlenmeyer flask and 500 µL of a 6 mM 
stock solution of biotin (stock solution made in DI water, sterile filtered, with the 
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minimum amount – a few drops – of 10N NaOH to enhance solubility of biotin) was 
added to this flask (final biotin concentration was 50 µM). 
Note: Always test well-in-advance (before beginning expression) that the pH of the biotin 
stock does not alter the pH of the insect media. For this: Mix the 500 µL of a 6 mM 
stock solution of biotin solution to 46 mL of SFX media and compare the pH of this 
mixture vs. that of the SFX media without the biotin solution added. This is a crucial 
step as the pH of the media is close to the pI of hemagglutinin and increasing the pH 
of the media could cause loss of protein due to precipitation at the pI. 
viii) After the 20-minute incubation, the cell suspension was added to the SFX media, mixed 
well, and incubated at 28ºC without CO2 for 72 – 96hrs.  
ix) The media was harvested by centrifuging the suspension at 2000xg for 10 min. The 
supernatant contains the hemagglutinin since the plasmid had a signal peptide to trigger 
secretion into the media. Hemagglutinin was purified using Ni-NTA resin. 
 
2.2.6. Protein Purification: 
Hemagglutinin has a His tag at the C- terminus, which was used to purify it by affinity 
chromatography using a Ni column/resin. This step was followed by size exclusion 
chromatography to separate the trimer fraction (desired) from larger protein aggregates.  
i) A fresh Ni Agarose column must be used per protein. The column was washed with 
plenty of water to remove the 20% alcohol storage buffer and equilibrated with ~ 5 
column volumes of equilibration buffer (chilled PBS, pH 8.0). 
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ii) The media supernatant was incubated with the Ni resin for 2-4 hours at 4ºC on a 
rocking platform, after which the mixture was poured through an empty column and 
the resin was allowed to settle in it while the supernatant flowed through.  
iii) The column was washed with copious amounts of wash buffer (15mL x 4 times) (50 
mM Na2HCO3, 300 mM NaCl, 20 mM imidazole, pH 8) after which the bottom of the 
column was capped with a stopper.  
iv) 3 mL of elution buffer (50 mM Na2HCO3, 300 mM NaCl, 300 mM imidazole, pH 8) 
was added to the column and allowed to incubate for 5 min, after which it was 
collected. This was repeated three times to collect a total of three fractions.  
v) In the meantime, a spin filter was washed with copious amounts of de-ionized water 
and chilled PBS was added to it, and was spun at 3000xg for 20 min at 4ºC.  
vi) The fractions were pooled, aside from keeping 20 µL of each for characterization by 
SDS PAGE, and were concentrated/washed three times with chilled PBS (spun at 
3000xg for 20 min at 4ºC). 
vii) This concentrate was passed through a size exclusion chromatography (AKTA, 
Superdex 200 10/300 GL increase). The trimer eluted at ~ 9 mL whereas the 
aggregate eluted at ~12 mL.  
   
2.2.7. Conjugation of HA, followed by Western blots: 
i) The steps outlined in section 2.2.3 were repeated to make more strep-NTs. This strep-
NT batch was split into two; to each batch of 500 µg of streptavidin-NTs, 750 µg of 
HA (head biotinylated or tail biotinylated) was mixed. The biotinylated HA (HT or TT) 
was expressed and purified as mentioned in sections 2.2.5 and 2.2.6. The excess/free 
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HA was removed using a sucrose gradient of 4%, 10% and 30% sucrose by spinning at 
175,000xg in an ultracentrifuge. It is essential that the sucrose solutions be removed 
carefully and discarded without disturbing the NT pellets. The pellet was resuspended 
in 20mM phosphate buffer (pH 7.4). Again, the nanotube concentration of HA-NT was 
calculated by repeating the above procedure of taking the absorbance at 808 nm and 
repeating above-mentioned calculations.  
ii) A western blot was performed to estimate loading of HA onto NT: a range of known 
amounts of HA-NT was taken (in terms of weight of NTs in ~100s of ng). Also, varying 
known amounts of HA alone were also used (these served as standards to help estimate 
the amount of HA loaded onto NTs). All samples were boiled in SDS at 80 ºC in a PCR 
machine for ~ 30-40 min after which they were characterized by gel electrophoresis. 
The proteins in the samples entered the gels, while the nanotubes remained in the wells 
itself. The proteins were transferred from the gels onto nitrocellulose membranes (for 
the western blot) and blocked in 5% BSA solution using a blot transfer apparatus. The 
primary antibody (1:2000 dilution in 1% BSA solution) used for the blot was an 
influenza HA anti-head antibody (PY102) obtained from our collaborators from the 
Icahn School of Medicine at Mount Sinai. The secondary antibody used was an anti-
mouse goat HRP-conjugated IgG (1:10,000 dilution in 1% BSA solution). The relative 
densities of the bands were estimated using the ImageJ software and plotting the linear 
range of HA standards loaded onto gels. Once we estimated the ng amounts of loaded 
HA, we could calculate the loading by dividing the HA amount (ng) by the NT amount 





2.2.8. Addition of Adjuvants and dilutions before vaccination: 
The HA-NTs (HT-NT and TT-NT) were diluted to make aliquots such that there would 
be sufficient HA loaded onto the tubes for each mouse to receive 5 µg of HA. The 
volume injected per mouse per round of injection was 50 µL, out of which 45 µL was 
the vaccine and 5µL was the adjuvant, poly I:C. A quick vortexing before and after 
poly I:C addition was helpful in ensuring proper mixing. 
  
Note:  Apart from the conjugates with HA oriented in two ways, a required control required 
for the in-vivo testing of a vaccine is the “vehicle-only” control which should ideally 
lack the antigen or in our case, HA. The aim here is to show that the vehicle alone does 
not trigger the broadly neutralizing response. I decided to use PEG-NTs at this stage 
and not Strep-NTs for the “vehicle-only” control.  Streptavidin being ‘more accessible’ 
to the immune system in the case of the Strep-NTs might not make for an appropriate 
control because the streptavidin in the case of the HA-NT conjugates would be within 
the ‘inner layers’ i.e. sandwiched between PEG on one side and HA on the other and 
closely stacked together on NTs; therefore, streptavidin would not be as easily “seen” 
by the immune system. Hence, I felt that a more appropriate control would be PEG-
NT. 
 
2.2.9. In-vivo cH5/1N1 challenge: 
The immunizations and viral challenge experiments were carried out by our 
collaborators at the Icahn School of Medicine at Mount Sinai. For each type of sample 
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(whether HT-NT, TT-NT, or NT-PEG ‘vehicle-only’ control) five mice were 
vaccinated, which yields a total of fifteen vaccinated mice. The HA-NT conjugates was 
administered twice, as one prime and one boost, to BALB/c mice, with a gap of 3 to 4-
weeks. After both rounds of vaccination, blood samples were collected for ELISAs to 
assess anti-stalk antibody titers. After the second round of vaccination, another 4 weeks 
were allowed to pass after which the mice were challenged with a ‘cH5/1N1’ virus. 
CH5/1N1 is a chimeric virus, modified to have the same stalk region as that of H1 
hemagglutinin, but a different HA head region (belonging to H5 subtype). After the 
challenge, the mice were monitored for the loss in their body weight; if the loss 













Figure 5: Schematic representation of a Chimeric H5/1 hemagglutinin: 













From the SEM image shown above, the size of raw/pristine SWNTs are easily above 
1µm, which is too large for use in an in-vivo system. These SWNT were cut with the 
help of a mixture of concentrated sulfuric and nitric acids.   
 










Figure 6: SEM images of raw single walled carbon nanotubes  
Figure 7: TMB based ELISA data for HRP-NT (sample) and BB-NT (biotin blocked 
control), averaged over three different batches; the signal for the BB-NT is very low.  
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HRP was a model protein, loaded onto nanotubes to test the methodology and to 
quantify the loading of HRP on NTs. The ELISA data was analyzed and plotted in 
Figure 7. The samples (and corresponding controls) were taken from three different 
batches of conjugation reactions.  From the figure, we see that the HRP-NT samples 
had a loading ranging from 0.35 - 0.5 mg HRP/mg NT. The loading for the biotin 
blocked controls (BB-NT) was significantly lower, consistent with a biospecific biotin-
mediated immobilization of HRP onto the streptavidin-coated nanotubes with minimal 
non-specific adsorption.  
 
2.3.3. TEM imaging of biotin-gold coated NTs:  
Figure 8 shows TEM images taken of 5nm gold nanoparticle coated nanotubes (NTs 
themselves are not easily visible). The streptavidin coated NTs were mixed with an 
excess of biotin-gold to saturate the streptavidin sites. This was imaged by my 
colleague, Chad Varner. 
 
These images show that the nanotubes are well covered by the gold nanoparticles and 
corroborate the ELISA results, implying that the nanotubes can be loaded with 
hemagglutinin. These images also show that the NT length has been reduced after the 
cutting them with acid. The length of the NTs was found to be between 50-250 nm, 















2.3.4. Western Blots:  
Western blots were done to quantify the amount of HA that was loaded onto the 
nanotubes. 
 




ImageJ was used to analyze the images to quantify the amount of HA using 
densitometry. First the standard curve was plotted with the ‘HA standards’ data. This 
was used to estimate the amounts of HA loaded onto the HA-NT conjugates. The 
loading for HT-NT was 1.1 mg HA per mg NT and for TT-NT was 1.2 mg HA per mg 
NT.  
 
Figure 8: Transmission electron microscopy images of 5nm gold coated nanotubes 
(scale bar reads 20nm)  
(a) (b) 
Figure 9: Western blots to semi-quantitatively assess loading of HA on 
NTs (a) 200-50ng of HT-NTs in the first five lanes, 80-40ng of HT 
standards in the next five lanes, (b) 200-50ng of TT-NTs in the first five 
lanes, 80-40ng of TT standards in the next five lanes 
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The anti-stalk antibody titers (reported by our collaborators at the Icahn school of 
Medicine at Mount Sinai) were measured by performing an ELISA on the mice sera 
collected after both rounds of vaccination (figure 10). The sera were tested for 
antibodies that would bind to a chimeric H6/1 hemagglutinin with the head region of 
H6 and stalk region of H1. We see a relatively higher stalk-binding antibody titer in the 
sera from the mice receiving the head tag HA – NT (HT-NT) where the stalk region 
faces outwards as compared those seen either in the negative vehicle-only control and 
the TT-NT. Therefore, at the end of two rounds of vaccinations, we concluded that 
there was a difference in the stalk antibody titer triggered by the HT-NT vs. TT-NT.  
Figure 10: Measure of anti-stalk antibody titers from BALB/c mice sera collected after 
two rounds of vaccination; tested samples include vehicle-only NT-only: negative 
control (●), Head tag NTs (■) and Tail tag NTs (▲). Tested for binding against 
chimeric H6/1 hemagglutinin – with the head region of H6 and tail region of H1 
27 
 
This experiment was followed by a cH5/1N1 viral challenge for the mice receiving the 
vaccines and control. We observed that after two immunizations rounds, the difference 
between the protection offered by our proposed vaccine HT-NT was more pronounced 










Figure 11 shows the % weight lost by the BALB/c mice for 14 days after infection with 
a chimeric cH5/1N1 virus. Here, we see that the mice receiving the HT-NT recovered 
from the infection, but the mice receiving both TT-NT (control vaccine) and the 
vehicle-only control lost more than 25% of their weight and had to be euthanized per 
the standards set by IACUC. This proves that the protection offered by the novel 
vaccine is due to the orientation of hemagglutinin on the vaccine scaffold.  
 
Figure 11: Percentage weight loss in BALB/c mice; monitored for 14 days’ 
following a chimeric viral H5/1N1 challenge after two rounds of immunization with 














Figure 12 corroborates the data shown in figure 11 as it shows the survival data for the 
BALB/c mice after two vaccination rounds followed by the viral cH5/1N1 challenge. 
Most of the mice receiving our proposed vaccine (HT-NT) survived the challenge but 
those receiving the other two constructs (TT-NT and vehicle-only control) required 
euthanization. 
 
2.3.6. Characterization of hemagglutinin (antigen): 
Although the preliminary results to assess the orientation dependence in-vivo had been 
encouraging so far, antigen characterization was crucial to this study before we could 
attempt the heterologous viral challenge (against whole H5 and H6 viruses). The PR8/ 
H1 hemagglutinin that we had used for our initial immunization experiments was 
expressed in insect cells (High Five cells) and purified using affinity chromatography 
Figure 12: Survival data for the cH5/1N1 viral challenge in BALB/c mice 
after two rounds of immunization; HT-NT (▬▬), TT-NT (▬▬), and 
vehicle-only control (▬▬) 
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(Ni resin based) by our collaborators and shipped to us on ice. We characterized this 
protein using Transmission electron microscopy (TEM) and size exclusion 
chromatography (SEC).  
Figure 13 shows the Transmission electron microscope image of ‘free’ hemagglutinin; 
it reveals rosettes of trimers suggesting that hemagglutinin can form large soluble 











Size exclusion chromatography data for HA (HT) and HA (TT) (Figures 14a and 14 b, 
respectively) confirmed that both proteins were a mixture of trimers and larger 
aggregates.  While the initial immunization results were encouraging, we reasoned that 
a size exclusion chromatography step that separated the trimer from the aggregate was 
essential before conjugating the hemagglutinin onto NTs to study the orientation 
dependence.   
Figure 13: Transmission electron microscopy image of hemagglutinin 


















We therefore decided to express and purify hemagglutinin in our lab so that we could 
better control the purification processes. Another advantage was that we could avoid 
the overnight shipping and that the conjugation of hemagglutinin onto nanotubes could 
be done the very same day.  
(a) 
Figure 14: Size Exclusion Chromatography plot for hemagglutinin variants 
















After multiple attempts in mammalian cell culture, hemagglutinin was successfully 
expressed in insect culture. Two insect cell lines were considered during the 
optimization process: SF9 and High Five cells. Using a commercial transfection 
reagent, Xtremegene HP to express these proteins, SF9 cells gave better yields ~ 0.5-
1mg HT/L culture and 2.5-3.5 mg TT/L culture.  As shown in figure 15, H1 HA wt., 
HT and TT were expressed and purified using Ni NTA affinity chromatography.  
The HT and TT were run through size exclusion chromatography, and the results are 
as shown below in figure 16 (a) and (b). Although the proteins were successfully 
expressed and purified, we observed a larger amount of aggregate relative to trimer. 
Also, both HT and TT had the AviTag sequence inserted in the head and tail region 
respectively and needed to be biotinylated ex-vivo. When this was attempted, a large 
                            A                B               C 
Figure 15: SDS PAGE gel image, Set A: HT HA, B: TT HA, C: H1 HA wild type.  
Lane order: 1. Expression Media with protein 2. Flow-through from Ni NTA 
affinity chromatography 3. Eluted fraction. The red arrow indicates purified 
protein  
1    2    3 1     2     3 1     2     3  
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amount of protein precipitated irreversibly. This accounted for about 70 - 80% protein 



























Figure 16: Size Exclusion Chromatography plot for hemagglutinin variants (a) 




To overcome these challenges, we next attempted baculoviral expression of HA, which 
gave us yields comparable to that of the transfection reagent (Figure 17 (a) below). The 
baculoviral vector pFastBac Dual allowed for the insertion of two genes which could 
be expressed simultaneously, and this was advantageous, because hemagglutinin could 
be expressed alongside an in-vivo biotinylation enzyme, BirA. This allowed for the in-
vivo biotinylation of both HT and TT, when biotin was supplemented into the media. 
Baculovirally expressed HT was run through size exclusion chromatography and 
relatively larger fraction of trimer was observed over aggregate. 70 – 80% of the 
biotinylated HT expressed was in trimer form and was extracted after SEC and used to 

























Baculovirally expressed TT was still predominantly aggregate (figure 18 (c)), but the 
expression yield of the TT variant was higher (~ 3 mg/L) than that of the HT variant 
(~1mg/L); this enabled scale up of expression to yield sufficient “trimer only” fraction 
for our conjugation experiments.  
Circular Dichroism was also used to characterize the expressed hemagglutinin (H1 HA 
wt. at concentration at 0.3 mg/ml and 0.1 cm path length) as shown in figure 18 (b); the 
CD spectra for HA and was similar to one published in the literature (figure 18 (a)) 
[45]. The CD spectrum in Fig. 18 (b) indicates a rich beta-sheet structure, with a minima 
appearing close to ~ 215nm. It has been shown that the globular head region of HA is 
rich in anti-parallel beta-sheets, and the rest of HA1 which runs along the stem region 
Figure 17: (a) Expression and affinity based purification of baculovirally expressed HT-
biotin, Lane order: 1. Expression Media with protein, 2. Flow-through from Ni NTA 
affinity chromatography, 3. Eluted fraction.  (b): Size exclusion chromatography on 





has a beta-sheet structure. The HA2 region, predominantly consisting of the stem, is 


















Figure 18: (a) Circular Dichroism spectra adapted from Wang C. et al., 2009 [45], 













































To test if the hemagglutinin was being secreted after in-vivo biotinylation, an ELISA 
was done to probe for biotin, using streptavidin-HRP for detection. As shown in figure 
19 (a), the HT expressed using baculoviruses gave a significant signal for biotin, 
comparable to commercially purchased biotinylated BSA. The HT and TT expressed 
using transfection reagent (labelled as “XG” in the plot) which was not in-vivo 
biotinylated or a negative control, GFP, gave minimal signal for biotin. A “gel-shift” 
assay was done too, to verify the presence of biotin as shown in figure 19 (b). When an 
excess of streptavidin was mixed with the biotinylated HT, we see a disappearance of 
the HT band (decrease in intensity) since it forms larger molecular weight complexes. 
A similar trend was seen with commercial biotin-BSA. No such decrease in band 



























2.3.8. Relative binding of HA antibodies onto hemagglutinin conjugated to Streptavidin: 
The relative affinities for two different HA targeting antibodies; one against the head 
region (Ab PY102) and the other against conserved epitopes in the stalk (Ab C179) 
were tested to see if there was a difference in their binding when HT was oriented 
differently (figure 20). In one case, HT was allowed to coat 96-well plates freely i.e. 
no specific conformation was enforced whereas in the second case, the wells were first 
coated with streptavidin and HT was allowed to bind in the presence of a blocking 
agent (BSA). We see higher binding of the anti-stalk antibody to HT than the anti-head 
(b) 
Figure 19: Probing for successful in-vivo biotinylation (a) ELISA using streptavidin-
HRP to detect biotinylated protein, the controls HT and TT are not biotinylated 
(expressed with transfection reagent ‘XG’) with the AviTag represented in black, 
‘blocked’ represents wells blocked with Bovine Serum Albumin (BSA), GFP and 
‘blocked’ both negative controls (b) ‘Gel-shift’ assay to assess shift in band or 
reduction in original band intensity due to formation of higher MW complexes via 
biotin-streptavidin interaction. Set A: HT-biotin expressed baculovirally, B: 
Commercial BSA-biotin, C: HT with AviTag, but not biotinylated, Lane order 1: 
protein alone, 2: streptavidin (large excess), 3: Protein and streptavidin mixed; equal 
amounts of protein (being probed for biotin) were used in lanes 1 and 3  
 
1    2    3 1    2    3 1    2    3 
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antibody, when HT was immobilized in a specific orientation, with the stalk facing 











2.4. Future work:  
2.4.1.  Heterosubtypic in-vivo challenges after two rounds of vaccination:  
Although encouraging preliminary results were seen after two rounds of immunization, 
where the HT-NT provided complete protection after a chimeric H5/1 viral challenge, 
the antigen used may have been in a partially aggregated form. The same experiment 
therefore must be repeated with conjugates functionalized with purified HT and TT 
trimers (using an additional round of size exclusion chromatography to extract 
Figure 20: ELISA to probe relative binding of head-binding antibody PY102 (■) vs. stalk 
binding antibodies C179 (■) – to see the effect of orientation of HT; ‘HT only’ is where 
HT was freely allowed to coat wells – arbitrary orientation, whereas ‘streptavidin-HT’ is 
where HT is made to orient itself with the tail facing outward by binding to streptavidin 
coated wells.  
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hemagglutinin trimers), followed by a cH5/1N1 challenge (to monitor whether the 
antibody levels elicited after 2 vaccine rounds are sufficient to mount a neutralizing 
response) and a heterosubtypic challenge with H5 viruses (to assess the breadth of the 
neutralizing response). Another experiment that could be done is using H1 HA for the 
first round of vaccination, but use another subtype of HA (within group 1, say H2) for 
the second round. Since the stalk regions are similar, this might help amplify the 
orientation dependence. The viral challenge could be repeated with H5 viruses.  
 
2.4.2. Hemagglutination assay:  
Hemagglutination assays are traditionally performed to measure the levels of viral titers 
in sera. It exploits the ability of an influenza virus to attach itself to the surface of RBCs 
and cause clumping or hemagglutination [47]. A hemagglutination assay will be 
performed as another means to assess the orientation of the HA loaded onto the NTs. 
In the conjugates with the head of HA towards the solution (away from the nanoscale 
support), we expect to see hemagglutination (RBC clumping). In the case where the 
tail of HA is towards the solution, we should ideally see little to no agglutination. This 
will help verify that the HAs are oriented correctly on the NTs.  
 
2.4.3. Broadly neutralizing vaccine against both groups of Influenza: 
So far, we have attempted to generate bnAbs against group 1 viruses. We could attempt 
to elicit bnAbs that neutralize both groups. Another experiment that would be done is 
using a group 1 viral HA (H1) to prepare the first round of vaccines, but use a group 2 
viral HA (say H3) to make the second round of vaccine. The breadth of the neutralizing 
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repertoire can be studied with ELISAs to measure anti-stalk titers and performing a 
heterosubtypic mice survival challenge (with viruses from both groups, say an H5 
(group 1) and an H7 (group 2) challenge). 
 
2.5. Conclusion and Discussion  
In conclusion, we have designed a vaccine that has shown protection against a chimeric virus with 
the hemagglutinin having the same stalk region as that used in the vaccine (H1) but a foreign head 
(H5). The construct was tested for successful protein loading and estimated the hemagglutinin 
loading onto the nanotube scaffold to be ~ 1mg HA/mg nanotube scaffold. The antigen, 
hemagglutinin was also well characterized, using Transmission Electron Microscopy and Size 
exclusion chromatography. It was observed that HA was aggregated so we took on the expression 
and purification from our collaborators to better control the purification process.  
Hemagglutinin was expressed using insect cell culture that was infected with baculoviruses that 
expressed the head tagged biotin or tail tagged biotin version of hemagglutinin. Baculoviral 
expression provided a twofold benefit: 1. HT was found to aggregate a lot less than in the case 
when it was expressed using a transfection reagent and 2. In-vivo biotinylation allowed for us to 
have more protein to work with since ex-vivo biotinylation caused ~75% of the protein to 
precipitate out. A size exclusion chromatography step was required to follow the affinity 
chromatography step in close succession so as to be able to quickly extract the trimer fraction and 
minimize the extent of aggregates formed. The hemagglutinin trimer was then conjugated onto the 
streptavidin coated nanotubes.  In future work, we will test the efficacy of these well-characterized 
vaccine candidates and their ability to protect mice from a heterosubtypic viral challenge. 
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3. Multivalent conjugates of hemagglutinin-binding proteins 
3.1. Introduction 
The goal of this project was to design polyvalent therapeutics against influenza. Our collaborators 
(Baker Lab) at the University of Washington computationally designed proteins that bind to 
conserved sites on hemagglutinin [27], [28]. The binding sites of these proteins were ‘chosen’ 
based on the conserved binding sites of some broadly neutralizing antibodies such as CR6261 and 
F10 [27], [28]. Three key binding ‘hotspots’ (called HS) were selected; one (HS1) was the TRP21 
residue which made aromatic stacking interactions with the Phe side chains on the ‘hemagglutinin-
binding proteins’ or HB proteins, another (HS2) was the van der Waals interactions made by the 
hydrophobic groove (in which the fusion peptide resides) and HS1, and thirdly (HS3), hydrogen 
bonding interactions on the alpha helical region of the HA2 chain (THR41 and ILE45) [27], [28]. 
The structure of H1 HA0 was obtained from the protein data bank (PDB 1RD8) and was modified 
using RASMOL to highlight the binding sites for the HB proteins (in red in figure 21). The two 







 Figure 21: Structure of stem of HA monomer (PDB 1RD8) in green, with binding sites 
of HB proteins highlighted in red, blue and purple (reported binding ‘hotspots’) 
42 
 
3.2. Materials and Methods: 
Initially, monomeric versions of the two HB proteins were expressed, purified and tested so as to 
determine their IC50 values. The goal was to express/synthesize multimeric versions of HB proteins 
that will have IC50 values orders of magnitude lower than that of the monomer alone. The design 
of homodimeric versions of the HB proteins was attempted, for which the optimum linker lengths 
had to be computed. Some of the protein expression and purification techniques used are listed 
below:  
 
3.2.1. Protein Expression: 
 
i) The plasmid containing the HB protein sequence was transformed into the NiCo21 
(DE3) cell line (catalog# C2529H) according to the protocol suggested on the NEB 
(New England BioLabs) website.  
ii) After transformation, the bacteria was allowed to grow in SOC (super optimal broth) 
media (without antibiotic) for 1 hr at 37ºC. 500µL of this culture was used to inoculate 
a fresh 5 mL pre-autoclaved LB (Luria Bertani) media stock (with antibiotic: 
kanamycin) near a flame, and was incubated at 37 ºC with shaking, overnight.  
iii) 1L LB media was prepared that evening (by dissolving 25g of LB media powder in 1L 
culture flasks with distilled water). The media was autoclaved and set aside.  
iv) Scale up: The following morning, 1 mL of antibiotic (kanamycin) was added to the 
scaled-up media near a flame, to maintain sterile conditions. Subsequently, 1 mL of 
inoculum (that was left overnight at 37ºC) was added to the 1L flask.  
v) The flask was placed in a shaker incubator and left at 37ºC for 4 to 5 h. This is when 
the bacteria are allowed to grow until they reach logarithmic phase.  
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vi) 400 µM of freshly prepared IPTG solution was added per liter of inoculated media. The 
temperature of the shaker incubator was reduced to 16ºC, and was incubated overnight.  
vii) The next day, the cells were pelleted by spinning at 6000xg for 1 h, while the 
supernatant was discarded.  
viii) The pellets were made to undergo repeated freeze-thaw cycles first to lyse cells. 50 mL 
of lysis buffer (50 mM Phosphate, 500 mM NaCl, 25 mM imidazole, 0.2 mg/ml DNase, 
1 mM PMSF, pH 8.0) was added to a 1g pellet.   
ix) The pellet was homogenized in the lysis buffer and then sonicated (to completely lyse 
cells) for 5 minutes in an ice bath to ensure that proteins do not get denatured due to 
over-heating.  
x) After cell lysis, the cell debris was spun down at 20,000xg for 1h. The supernatant 
(contains the proteins) was collected. The pellet should be discarded only if the protein 
is not expected to be present in inclusion bodies.  
 
3.2.2. Protein Purification: 
The proteins being expressed have a His tag on either the N- or C- terminus, which can 
be used to purify them using a Ni column/resin using the principle of affinity 
chromatography.  
i) A fresh Ni Agarose column must be used per protein. The column was washed with 
plenty of water to remove the 20% alcohol storage buffer and equilibrated with ~ 5 
column volumes of equilibration buffer (50 mM Phosphate, 500 mM NaCl, 25 mM 
imidazole, pH 8.0). 
Note:   A high NaCl concentration was maintained i.e. 500mM to minimize non-specific 
adsorption of irrelevant proteins onto the Ni-NTA resin.   
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ii) The lysate was passed through the column, while the flow through was collected.  
iii) The column was washed once again with ~ 3 column volumes of equilibration buffer.  
iv) 10 column volume washes were performed with 50 mM and 100 mM imidazole 
buffers, pH 8.0. All washes were collected. The 100 mM wash was collected as 
fractions.  
v) Finally, the protein was eluted with 10 column volumes of 400 mM imidazole wash, 
while collecting fractions.  
vi) Gels were run on the fractions to assess which fraction had the protein of interest with 
desired purity. The absorbance at 280 nm was taken to determine the protein 
concentration.   
   
3.3. Results: 
3.3.1. Rationale behind optimum linker length calculations:   
The linker length analysis was based on a paper on the thermodynamic analysis of the 
effect of linker length on the avidity of multivalent interactions [48]. This analysis 
showed that the avidity of a homodimeric protein can be enhanced by optimizing the 
linker length connecting the two proteins. The parameter that is crucial for 
consideration is called the effective concentration (Ceff(r)), which is a function of “r” 
(the distance between the adjacent binding sites on the receptor) [49], [50]. Ceff is a 
function of the probability that the linker ends are at a distance “r” apart [48]. Another 
crucial parameter to be considered is the rRMS distance, that is, the root mean square 
distance between the ends of the flexible linker. The optimum rRMS distance (where the 
value of Ceff is maximum) is equal to “r” [49]. The free energy/avidity of binding has a 
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weak dependence on linker length. Consequently, linker lengths that are somewhat 
longer than optimum will also be effective in enhancing the avidity of a multivalent 
interaction [48]. However, the extended length of the polymeric chain cannot be less 
than “r”; otherwise simultaneous binding of the dimeric conjugate to two sites on the 
target receptor would not be possible [48]. The other extreme scenario, where the linker 
is much longer than the optimal value, would also diminish the benefit of polyvalency.  
 
3.3.2. Inhibitory activity data for HB monomers:  
Our collaborators at Emory University tested both HB monomers (HB36.6 and 
HB80.4) for their ability to inhibit influenza infection. The results for the inhibitory 
activity tests are shown in Figures 22 (a) and (b); the IC50 was calculated to be 17 nM 
































3.3.3. Optimum peptide linker length calculations for HB homodimers:  
For calculating optimum linker lengths, the PDB (protein data bank) structures 3R2X 
(HB36.3 bound to HA) and 4EEF (HB80.4 bound to HA) were studied. The binding 
sites being targeted by the homodimers are those present on adjacent monomers in a 
hemagglutinin trimer. The peptide linker connects the C-terminus of one HB protein 
bound to hemagglutinin to the N-terminus of an adjacent one.  The distance between 
these termini (i.e., the first estimate of the “end-to-end” distance for the linker), was 
8.3 nm for HB36.3 and 5.2 nm for HB80.4. A linear path from the C-terminus of one 
HB protein to the N-terminus of an adjacent one would, however, “go through the HB 
(b) 
Figure 22: Inhibitory activity plots - averaged over experiments performed in 




protein”, and this constraint would be expected to further increase the optimal RMS 
length of a designed linker. 
To ascertain how many repeats of the –GGSGG- linker are required to span this arc 
length, we assume that i) the -GGSGG- linker fits a worm-like chain model, ii) the 
peptide bond contour length (l = the distance between adjacent alpha carbons on a 
peptide chain; the distance between two amino acids = 0.38nm) [51], iii) persistence 
length (P = measure of stiffness/flexibility of polymer) = 0.45nm [51], the following 











































Number of peptide residues 
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From the above plot (figure 23), we see that the ideal RMS linker lengths would be ~ 
200 amino acids (or 40 repeats of GGSGG linker) for HB 36.3 and 80 amino acids (or 
16 repeats of GGSGG linker) for HB 80.4. A range of GGSGG repeats were chosen 
around these values for testing. 
 
3.3.4. Expression, Purification and activity testing: 
Due to difficulty with the bacterial expression of dimers with large repeats of GGSGG, 
we decided to test the concept of polyvalency using 75 amino acid linkers of GGSGG 
(15 repeats of the GGSGG unit) for both monomers, HB36.6 and HB 80.4 (figure 25); 
to assess the improvement in the avidity of conjugate for the receptor over the affinity 
















Figure 24: Gel image of IMAC purified fractions of bacterially expressed 
monomers HB36.6 & HB 80.4, and dimers HB36.6-15-36.6 and HB80.4-15-











These HB monomers and dimers were tested in an ELISA to assess how effectively 
they can inhibit the binding of hemagglutinin-head and stalk targeting antibodies. The 
hemagglutinin used for this inhibition assay was H1 PR8/34 HA, which was first 
immobilized onto 96-well plates, and subsequently blocked with 5% BSA. After the 
blocking was complete, the HB monomers or dimers was added to each well in the 
presence of 2% BSA. This step was followed by the addition of either the anti-head or 
anti-stalk antibody – which was detected with a secondary mouse Ab linked to HRP. 
Also, both monomers and dimers were tested at the same “per HB concentration” or 
effective concentration of 0.1mg/ml. The results are indicated in figure 25 below. 
Neither the monomers nor the dimers seem to affect the binding of the hemagglutinin-
head binding antibody, PY102 vs. the ‘no inhibitor’ control (No HB protein was added 
to these hemagglutinin-coated wells); this is to be expected since the HBs are 
hemagglutinin-stalk binding peptides.  
 Both HB monomers and dimers successfully inhibit the hemagglutinin-stem binding 
antibody, C179 vs. that indicated in the ‘no inhibitor’ control. At the same effective 
concentration, both the dimers inhibited the binding of stem targeting antibody, C179 
to a greater extent than the monomers. More specifically, a fivefold decrease in signal 
was observed with the HB36.6 dimer (15 repeats of GGSGG) vs. that seen with 
HB36.6, and a fourfold decrease in signal was observed with the HB80.4 dimer (15 




















3.4. Future Work and Conclusion: 
Dimers of both HB proteins with 15 repeats of -GGSGG- linkers were bacterially expressed. The 
optimum linkers for both HB36.6 and HB80.4 were found to be 60 repeats and 20 repeats of 
GGSGG respectively. Although 15 repeats of GGSGG were the less than optimum for both 
constructs based on optimum linker length calculations, they were used to prove the concept that 
polyvalency provides for the making of more potent inhibitors that bind to hemagglutinin with 
higher avidity, and that can block the binding of competing antibodies more effectively than the 
monomeric HBs could. Polyvalent constructs with a larger number of repeats of -GGSGG- were 
difficult to express.   
Figure 25: ELISA data showing enhanced inhibition of stalk-binding antibody C179 (■) by 
dimeric constructs at the same “per-HB” concentration (of 0.1mg/ml) as monomeric 
peptides. Anti-head antibody PY102 (■) binding is not affected by the presence of either 
the HB monomers or dimers.  
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In future work, we will  
i) Perform a dose-response study to assess and compare the IC50 of the dimers vs. that of 
the monomers.  
ii) Compare the ability of the homodimers and monomers to neutralize influenza viruses 



















4. Multivalent conjugates that target an HIV co-receptor, CCR5 
 
4.1. Introduction: 
The goal of this project was to make polyvalent antagonists that bind to different sites on CCR5 
as potential inhibitors of HIV infection. CCR5 is a G-protein coupled receptor, which has a key 
role to play in the cellular entry of HIV. The crucial sites on CCR5 for HIV entry are the N-
terminus and the second extra-cellular loop (ECL2). The N-terminus of CCR5 aids in gp120-CCR5 
binding; antibodies against the N-terminus inhibit this process [52], [53]. ECL2 plays a vital role 
in the process of HIV infection as it allows for conformational changes in the env to occur so as to 










Leukotoxin E (LukE) interacts directly with the second extracellular loop (ECL2) loop of CCR5 
[53], [54]. The interaction of LukE with CCR5 was inhibited by CCR5 ligands, Maraviroc (anti-
HIV drug), and antibody 45531 directed against ECL2 (C-terminal side) [37]. Literature was 
studied to identify other CCR5 binders that would not hinder the binding of LukE to CCR5.  
 













Two antibodies were selected; RoAb13 and RoAb14. RoAb13 binds to the first 8-12 residues on 
the N term of CCR5 (figure 27), whereas RoAb14 binds to two sites on ECL2 which lies on either 
side (N-terminal and C-terminal) of the ECL2 receptor [38]. RoAb13 was expressed using 
mammalian cell culture to ensure that it shows binding to the N terminus of CCR5.  
To design polyvalent molecules comprising LukE, RoAb13 and RoAb14, -GGSGG-, poly-
glutamic acid (PGA) chains or PEG would make appropriate linkers, as they can be made to span 
a large range of possible RMS end-to-end distances. The dimers that we designed were: LukE-
RoAb13, LukE-RoAb14 and LukE-LukE and LukE multimers with PGA linkers. Since attaching 
whole length antibodies would make the entire construct bulky and difficult to bacterially express, 
single chain fragment variable (scFv) versions of the same were used. ScFvs are fusion proteins 
consisting of a variable heavy chain and a variable light chain of an antibody, which are connected 
by a GGSGG linker [54]. Both Leukotoxin E and the heterodimers, LukE-RoAb13 and LukE-
RoAb14, were expressed bacterially [55]–[57]. The heterodimers were linked with a GGSGG 
Figure 27: Structure of CCR5 receptor (PDB 4MBS) with the RoAb13 (at N term, in 
red) and RoAb14 (2 points on ECL2, min yellow) binding sites highlighted 
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linker with 15, 20 and 30 repeats of the -GGSGG- unit, while the LukE homodimer was made 








To prepare PEG based homodimers of LukE, we chose to use ‘azide-DBCO’ copper free Click 
chemistry, since it has been reported that this reaction gives good yields, is highly selective, has 
good physiological stability and can be carried out in a wide range of buffer conditions and pH 
values [58].  PEGs containing two reactive DBCO (Dibenzocyclooctyne) groups were 
commercially purchased.  
To introduce the reactive azide into Leukotoxin E: an unnatural amino acid was incorporated into 
the protein, on the C-terminal end where the stop codon was replaced with a ‘TAG’ codon or the 
‘amber stop codon’, which can be made to code for the unnatural amino acid (p-Azido 
Phenylalanine) [59], [60]. The unnatural amino acid was supplemented to the medium during 
bacterial expression of Leukotoxin E. For the successful incorporation of this amino acid, an 
orthogonal translation system was used; the vector ‘pEVOL’ was co-transformed along with the 
pET28b(+) vector that contained the gene insert for Leukotoxin E[60]. The pEVOL vector coded 
for both aminoacyl-tRNA synthetase(s) (aaRS) and suppressor tRNA [59]. Aminoacyl tRNA 










synthetases aid in the conjugation of the amino acid to the corresponding tRNA, only after which 
it is shuttled to the respective site on the mRNA [61]. The suppressor tRNA is unique in that it is 
only aminoacylated by this specific synthetase encoded in the pEVOL vector, thus allowing for 
orthogonality, and the incorporation of a specific amino acid.  
The overall Leukotoxin E sequence was modified from ‘LukE-GGSGG-Hisx6-STOP’ to ‘LukE-
GGSGG-Amb-Hisx6-STOP’. The incorporation of the Amb codon between the hexahis tag and 
the GGSGG linker was crucial as it was a check for us to ascertain if the unnatural amino acid was 
truly incorporated into the protein sequence as we expected. If the ‘TAG’ codon was read as an 
unnatural amino acid codon, p-Azido Phenylalanine (F*) would be successfully inserted and the 
translation would continue to incorporate the hexahistidine tag, only after which the translation 
would terminate – such a protein would selectively bind to a Ni resin during affinity purification. 
If the ‘TAG’ codon was read as a STOP codon instead, translation would cease before translating 
the hexhistidine tag and such proteins would not bind to the Ni resin in the purification process 
and would be eliminated in the flow through.  
 
PGA (polyglutamic acid) linkers as the name suggests, contain multiple copies of glutamic acid. 
The free -COOH groups of the glutamic acid act as a reactive site for conjugation to amino-ethyl 
DBCO via EDC-NHS chemistry; this step is called “PGA activation”. At the end of the activation 
step, the PGA chain had multiple DBCO groups randomly attached to the scaffold, since chemical 
conjugation techniques made it difficult to control spacing and valency of reactive groups on the 
scaffold. 0.5% and 2% molar ratios of LukE-F* to monomer of glutamic acid were mixed to 
generate polyvalent LukE conjugates. 
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4.2. Materials and Methods: 
4.2.1. Bacterial Protein Expression: 
 
xi) The plasmid containing the Leukotoxin E or the dimer sequence was transformed into 
the NiCo21 (DE3) cell line (catalog# C2529H) according to the protocol suggested on 
the NEB (New England BioLabs) website.  
xii) After transformation, the bacteria were allowed to grow in SOC (super optimal broth) 
media (without antibiotic) for 1 h at 37 ºC. 500µL of this culture was used to inoculate 
a fresh 5mL pre-autoclaved LB (Luria Bertani) media stock (with antibiotic: 
kanamycin) near a flame, and was incubated at 37 ºC with shaking, overnight.  
xiii) 1L LB media was prepared that evening (by dissolving 25g of LB media powder in 1L 
culture flasks with distilled water). The media was autoclaved and set aside.  
xiv) Scale up: The following morning, 1 mL of antibiotic (kanamycin) was added to the 
scaled-up media near a flame, to maintain sterile conditions. Subsequently, 1 mL of 
inoculum (that was left overnight at 37ºC) was added to the 1L flask.  
xv) The flask was placed in a shaker incubator and left at 37ºC for 4 to 5 hours. This is 
when the bacteria are allowed to grow until it reaches logarithmic phase.  
xvi) 400 µM of freshly prepared IPTG solution was added per liter of inoculated media after 
which the temperature of the shaker incubator was reduced to 16ºC, and the culture was 
allowed to incubate overnight.  
Note:  To express a protein with an unnatural amino acid (p-azido phenylalanine) a similar 
expression protocol was followed except for the following changes: the pEVOL vector 
(chloramphenicol resistance) had to be co-transformed along with the expression 
vector. Also, other than the 1 mM IPTG that was added to the culture, both 0.02% w/v 
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of arabinose and 1 mM of p-azido phenylalanine (dissolved initially in DMSO to 
facilitate dissolution) was added alongside.  
xvii) The following day, the cells were pelleted by spinning at 6000xg for 1 h, while the 
supernatant was discarded.  
xviii) The pellets were made to undergo repeated freeze-thaw cycles first to lyse cells. 50mL 
of lysis buffer (50 mM Phosphate, 500 mM NaCl, 25 mM imidazole, 0.2 mg/ml DNase, 
1mM PMSF, pH 8.0) was added to a 1g pellet.   
xix) The pellet was homogenized in the lysis buffer and then sonicated (to completely lyse 
cells) for 5 minutes in an ice bath to ensure that proteins do not get denatured due to 
over-heating.  
xx) After cell lysis, the cell debris was spun down at 20,000xg for 1h. The supernatant 
(contains the proteins) was collected. The pellet should be discarded only if the protein 
is not expected to be present in inclusion bodies.  
 
4.2.2. Mammalian culture – Protein expression: 
Antibody fragments were expressed using mammalian cells, more specifically 293F 
cells. These cells were grown in suspension culture and seeded at a density of 3x105 
to 5x105 cells/mL for each pass to maintain the cell line.  
Note:  All cell culture was done in strictly aseptic conditions, in a BSL-2 cabinet. 
The protocol for transfection has been taken from the literature for the product sold by 
Thermo Fisher Scientific called ExpiFectamine 293. The protocol has been re-iterated 
below for the sake of clarity.  Also, mammalian suspension cell culture was performed 
in disposable 125mL Erlenmeyer flasks.  
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i) The transfections were done in batches of 30 mL. For each transfection/batch, on the 
day before the transfections were carried out: 60 million cells were seeded in 30 mL of 
Expi293 serum-free media (or at a density of 2x106 cells/mL) and incubated at 37°C in 
a humidified atmosphere of 8% CO2 in air on an orbital shaker rotating at 125 rpm. 
The viability must be above 95% for effective transfection and protein yields. 
ii) After 24 hours, the cell count/viability was assessed with Trypan blue stain.  
iii) For each transfection, 75 million cells were seeded in 25.5 mL of Expi293 media (the 
volume was made up to 25.5 mL with fresh media) in a 125 mL Erlenmeyer flask.   
iv) The DNA-transfection reagent complexes were made as follows:  
a. 30µg of plasmid DNA was diluted using OPTI-MEM reduced serum media (Cat. 
no. 31985-062) to a final volume of 1.5 mL. 
b. 81 µL of transfection reagent was diluted using OPTI-MEM media to a volume of 
1.5mL and was incubated for 5 minutes. Increasing the incubation time reduces 
transfection efficiency. 
c. The diluted DNA was added to the diluted transfection reagent to a final volume of 
3mL and mixed gently. This solution was incubated at room temperature for 20-30 
mins. This allows the DNA to form complexes with the transfection reagent.  
v) The DNA-transfection reagent was added to the seeded flask and mixed gently. This 
was incubated at 37°C in a humidified atmosphere of 8% CO2 in air on an orbital 
shaker rotating at 125 rpm. 
vi) After 16-18 h, 150 μL of ExpiFectamine™ 293 Transfection Enhancer 1 and 1.5 mL 
of ExpiFectamine™ 293 Transfection Enhancer 2 was added to the flask and returned 
to the incubator for 6-7 days.  
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vii) Since the antibodies were secreted into the media, the media was harvested and proteins 
were purified using the Ni-NTA agarose resin.  
 
4.2.3. Protein Purification: 
The proteins being expressed have a His tag on either the N- or C- terminus, which can 
be used to purify them using a Ni column/resin using the principle of affinity 
chromatography.  
vii) A fresh Ni Agarose column must be used per protein. The column was washed with 
plenty of water to remove the 20% alcohol storage buffer and equilibrated with ~ 5 
column volumes of equilibration buffer (50 mM Phosphate, 500 mM NaCl, 25 mM 
Imidazole, pH 8.0). 
Note:  A high NaCl concentration is maintained i.e. 500 mM to minimize non-specific 
adsorption of irrelevant proteins onto the Ni-NTA resin.   
viii) The lysate was passed through the column, while the flow through was collected.  
ix) The column was washed once again with ~ 3 column volumes of equilibration buffer.  
x) 10 column volume washes were performed with 50 mM and 100 mM imidazole 
buffers, pH 8.0. All washes were collected. The 100 mM wash was collected as 
fractions.  
xi) Finally, the protein was eluted with 10 column volumes of 400 mM imidazole wash, 
while collecting fractions.  
xii) Gels were run on the fractions to assess which fraction had the protein of interest with 
desired purity. The absorbance at 280 nm was taken to determine the protein 
concentration.   
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4.2.4. Activity testing using Fluorescence Activated Cell Sorting: 
i) 100,000 cells (either CCR5+ 293T cells or control 293T cells) were plated per well in 
a 96-well plate (25µL of a cell suspension at 4 x (10)6).  
Note:  Make sure to save some cells (both CCR5+ and the control 293T) for optimizing the 
gate selection and voltage on the Cell Sorter. 
ii) 50µL of known concentration of inhibitor was added to the cells and was incubated at 
room temperature for 30 minutes.  
iii) This was followed by the addition of 25µL containing 10 nanomoles of FLSC (Full 
Length Single Chain) to each well and was incubated at 4ºC for 30 minutes.  
Note:  FLSC is a fusion protein consisting of the HIV’s envelope glycoprotein gp120 and the 
human CD4; along with a human Fc region (for detection) [62], [63].  FLSC interacts 
with CCR5 at similar sites as HIV; at the N terminus and the Extra Cellular Loop 2 
(ECL2). 
iv) The cells in the plate were spun at 400xg for 4 minutes, and the supernatant was 
discarded by gently emptying contents into a sink and tapping the plate dry on a paper 
towel (carefully to not dislodge the cells by tapping too hard). The cells were 
resuspended with 100µL PBS. 
v) Step iv was repeated for a wash and the cells were resuspended in 100 µL of PBS. The 
plate is ready to be run on the Cell Sorter (run on High Throughput Screening 







4.3.1. Expression and Purification:  
Leukotoxin E was successfully expressed bacterially and the RoAb13 antibody was 
expressed in mammalian cell culture. They were initially tested for binding to CCR5+ 
293T cells using Fluorescence Activated Cell Sorting. As shown in figure 29, LukE 








































Subsequently, both LukE monomer and LukE-F* were expressed along with the six 
heterodimers: LukE-75-R13, LukE-100-R13, LukE-150-R13 (15, 20 and 30 repeats of 
-GGSGG- respectively), and similarly LukE-75-R14, LukE-100-R14, LukE-150-R14, 
where R13 and R14 are abbreviated versions of the RoAb13 and RoAb14 scFv. For 
simplicity, the heterodimers have been referred to in plots ahead (FACS data) without 
LukE being explicitly mentioned i.e. as 75-R13, 100-R13 and so on.  
LukE-F* was used to make conjugates with both di-DBCO 5k PEG and PGA. To 
prepare the PGA scaffold-based conjugates, two relative concentrations of LukE-F* 
were used: 0.5% and 2% molar ratios of LukE-F* to monomer of glutamic acid (or 
DBCO groups, assuming 100% conjugation of the amino-ethyl DBCO and carboxyl 
groups of glutamic acid) on the PGA scaffold. As shown in lanes 4 and 5 in Figure 30, 
Figure 29: Binding activity of monomeric Leukotoxin E (a) and antibody RoAb13 




the reaction resulted in a mixture of polyvalent LukE-PGA conjugates differing in 
valency (i.e., in the number of LukE proteins per polymer chain). These conjugates 
were tested as is (without additional purification). To make homodimers with PEG, 
LukE-F* and di-DBCO PEG were mixed in a 5:1 molar ratio (i.e. a 2.5:1 molar ratio 
of LukE-F* to reactive DBCO groups) to promote preferential formation of dimeric 
product over that of the mono-PEGylated product. The result is shown in figure 30 in 










For the purification of the homodimers, two rounds of size exclusion chromatography 
were found to be necessary to extract the dimeric product from the mixture; the first 
step used a prep-scale ‘superdex 16/600 200pg’ column and the second round used a 
‘superdex 200 10/300 GL increase’ column. The SEC plot for the first round is shown 
in figure 31. 
 





Figure 30: SDS-PAGE gel; Contents of lanes appear in the order:  
Lane 1: ladder, Lane 2: LukE, Lane 3: LukE-F*, Lane 4: PGA-LukE 0.5%,  
Lane 5: PGA-LukE 2%, Lane 6: mixture of LukE-F* and di-DBCO PEG (before 
SEC) – homodimer conjugation, Lane 7-10: select fractions after first round of SEC 
on the homodimer conjugation mixture  


















The first round of SEC did manage to separate a large amount of mono-PEGylated 
product and unreacted monomer, although some amount of LukE monomer remained 
– so another round of SEC was necessary to improve purity. Fractions corresponding 
to lane number 4-7 in figure 31 (b) were pooled to run through SEC once again.  




Figure 31: The figure shows (a) an SEC chromatogram for the purification of the 
LukE homodimer from the mixture of dimeric, mono-PEGylated product and 
monomer and (b) SDS PAGE gels on select fractions obtained after the first 
round of SEC purification 
(b) 
(a) 



















As seen in figure 32 (b), the second round of SEC yielded relatively pure LukE 
homodimer. The conjugation was started with 10 mg of LukE; after allowing for the 
reaction to complete and two rounds of size exclusion chromatography with selecting 
(a) 
Figure 32: The figure shows (a) an SEC chromatogram for the purification of 
the LukE homodimer from the mixture of dimeric and monomer and (b) SDS 
PAGE gels on select fractions obtained after the second round of SEC 








only certain fractions to carry forward, 300µg of homodimer was obtained, which was 
sufficient for the FACS assay.  
 
4.3.2.  FACS assay – Inhibition of FLSC binding: 
The nine homodimers, heterodimers and multimers were tested for binding to CCR5 
(+) 293T cells by competing with FLSC binding. This was to probe whether we observe 
enhanced avidity for the receptor with these polyvalent conjugates vs. the monomer 
(LukE or LukE-F*, depending on the case).  The results are shown in figure 33 (a) and 
(b).  
Of the conjugates tested, the most promising candidates were the 0.5% PGA-LukE and 
all three LukE-R14 heterodimers, of which LukE-75-R14 showed the most inhibition 
and LukE-150-R14, the least. Based on the inhibition assay, it was determined that 
LukE had an IC50 of ~ 1.3µM, whereas the LukE-R14 heterodimers had IC50s below 
78nM (lower concentrations need to be tested to determine a more accurate IC50), 
indicating a more than 17-fold improvement in avidity. Even at 78nM, ~ 85% inhibition 
was observed for LukE-75-R14 and LukE-100-R14. They prove to be promising 
candidates that should be characterized further. Based on the inhibition data for LukE 
multimers on the PGA scaffold (0.5%), the IC50 was ~ 1.3µM, as compared to that of 
























Figure 33: FACS assay – Inhibition of FLSC binding (a) with Luke heterodimers vs. 





4.4. Future Work  
4.4.1. Repeating the FACS assay:  
The LukE-RoAb14 heterodimers should be tested at even lower concentrations on a 
FACS assay against FLSC to get an accurate estimate of the IC50. Also, my colleague 
Ammar Arsiwala is currently working on making RoAb14 monomer (SUMO fusion) 
so as to facilitate successful expression the scFv version of RoAb14 in Escherichia coli 
bacteria [64], [65]. This would be an important control to include in further tests.  
 
4.4.2. Synergy tests – probing for polyvalency: 
While repeating the FACS assay, as an additional control, one could test inhibition by 
an equimolar mixture of LukE and RoAb14.The results would help confirm a role for 
divalency in enhancing avidity, i.e., test whether joining the two proteins by a linker of 
appropriate length will enhance avidity for the receptor relative to a mixture of two 
monomeric proteins.   
 
4.4.3. In-vitro testing against HIV:  
The LukE-RoAb14 heterodimers and the LukE-PGA (0.5%) multimers will be tested 








4.5. Conclusion and Discussion 
In conclusion, the LukE-RoAb14 heterodimers and the LukE-PGA (0.5%) multimers 
proved to be the most promising candidates in an FLSC inhibition-based FACS assay. The 
LukE-RoAb14 heterodimers indicated improvement in avidity to more than 17-fold 
whereas the LukE multimers, 6-fold. The FACS assay will be repeated to better 
characterize the IC50 values of these heterodimers. Also, RoAb14 monomer scFv would 
also be attempted to be expressed with the help of a SUMO fusion tag. These CCR5 binders 















5. Conclusion  
 
In this work, polyvalency has been used to design influenza vaccines and inhibitors targeting 
influenza hemagglutinin and an HIV co-receptor, CCR5. I have developed a strategy for displaying 
an antigen (hemagglutinin) polyvalently on the surface of an inert scaffold (PEGylated carbon 
nanotubes) in a controlled orientation. Our goal was to re-direct the immune response towards 
certain conserved epitopes, with the goal of making a ‘universal’ flu vaccine that would offer 
protection against a wide variety of viral strains. We have also optimized the antigen purification 
process by incorporating a size exclusion chromatography step following a metal affinity 
chromatography step. Constructs presenting these purified antigens polyvalently will soon be 
tested in-vivo.  
I have also made polyvalent molecules that targeting hemagglutinin and CCR5, which have shown 
enhancements in avidity relative to the corresponding monomeric ligands. The dimeric 
hemagglutinin-binding constructs inhibited the binding of stalk-directed antibodies to 
hemagglutinin by a significantly greater extent than the monomeric proteins at the same total 
protein concentration.  Heterodimeric and multimeric CCR5-targeting inhibitors have shown some 
promising initial results; the most promising being Leukotoxin E-RoAb14 heterodimers which 
were significantly more effective than monomeric Leukotoxin E at inhibiting the binding of a 
gp120-CD4 fusion protein (called FLSC; Full Length Single Chain) to CCR5. Polyvalency is thus 





Materials and Methods: 
 
A.1. Cutting and COOH functionalization of single walled carbon nanotubes (SWNT):  
i) 20mg of SWNT was weighed out (single walled carbon nanotubes, Unidym) and 
thoroughly dispersed into a concentrated acid mixture of sulfuric acid and nitric acid in 
the ratio of 3:1, where the total volume of acid was 4 ml acid/mg NT (i.e. 80mL).  
 
Note on safety measures:  
 Make sure you have personal protective equipment on (lab coat, gloves, and safety 
glasses).   
 Make sure that the weighing out of NTs is done in a fume hood.  
 Before weighing, remove any static on the container the NTs are to be weighed into 
(using a static gun); static disperses NT particles.  
 Clean up the area with a wet wipe after weighing the NTs.  
 Wear a double layer of nitrile gloves while measuring out acids.  
 Try to avoid acid spills. In case of spill: (a) prevent it from entering drains (b) dilute 
it with water, and then neutralize with soda ash (sodium carbonate) or calcium 
oxide. Absorb neutralized spill with absorbent material and subsequently discard.  
ii) The nanotubes were sonicated in this acid mixture in an ice bath for a total of 21-22 
hours (over a span of two days; ~ 11 hours each day of cutting), to reduce their length 
from >1µm to 100-500nm. The ice in the sonicator bath was not allowed to completely 
melt and was replenished every 20-30 mins. 
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Note:  The sonication should be done under a fume hood too, to minimize the formation and 
dispersion of aerosols. Make sure that 1. The water in the sonication bath is up to the 
optimum level as indicated within the bath, and 2. The acid level inside the flask 
matches that of the water level outside the flask to as to have maximum effect of the 
sonication. After “day one” of cutting, the acid-nanotube was quenched in 2L chilled 
DI water overnight (DI water was collected and chilled at 4 ͦC ~ 4 hours before. This 
suspension had to be concentrated down to ~ 5 mL and added to a fresh batch of 
concentrated acid mixture (prepared as done so previously) to resume cutting the 
following day. 
iii) After the acid-based NT cutting was complete, the reaction was quenched, by adding 
the acid mixture to 2L of chilled DI water. The COOH-NTs were filtered and re-
suspended in 100 mL of DI water. This was allowed to sonicate for 30 min – 1hr; as 
much time as it takes to re-suspend the NT clumps before diluting it into 2L of DI 
water, and the said process is repeated. Repeated washes of NTs were performed until 
the filtrate was neutral in pH (~3-4 washes, final pH of ~ 6, closely matching the DI 
water available via the grey tap). 
iv) Finally, a concentrated solution of COOH-NTs was made and freeze dried to remove 
the water. This will help determine the NT yield.  
Note:  When NTs in the dried form require to be weighed, make sure it is done under the fume 
hood.  
Note:  The SWNTs are purchased ‘raw’, and are cut with concentrated acid mixture of sulfuric 
and nitric acid. Acid “Cutting” is useful not just to size down the tubes but also to 
ensure that there are –COOH groups that are generated over the NT surface. The –
73 
 
COOH group improves solubility and provides for a site for further functionalizing the 
NTs. 100-500nm would seem like an optimum size range for the NTs so that the 
antigen-coated NTs will be immunogenic, yet small enough (i.e. < 500nm) so as to not 
be easily engulfed and eliminated by the reticulo-endothelial system.  
 
A.2. Freeze-drying protocol for carbon nanotubes:  
i)  An empty glass vial is weighed with and without the cap, and the weight is noted down. 
The nanotubes obtained after cutting are concentrated down to ~ 10 – 15 mL and stored 
in a 20 mL glass vial. This is placed at -80 ͦC for ~ 2 – 3 h, until all the liquid freezes.  
ii)  The vial is taken out of the freezer and the cap is kept aside, and replaced with an 
aluminum foil that wraps the mouth of the vial – with the edges pressed against the rim 
of the vial. One can also use parafilm to seal the rim, over the foil. A couple of fine 
holes are punches on the top of the vial.  
iii)  This vial is placed in the freeze drying container (glass) and sealed off with the rubber 
top/stopper. Make sure a metal connector is affixed to the top of the rubber stopper 
(which would be used to connect it to the main drying unit). On the drying unit: Make 
sure the valve connecting the low pressured unit to the atmosphere are sealed off 
initially (the triangular notch on the rotating port is 180ͦ (opposite) from the site where 
the metal connector is to be inserted), after which the metal connector (connected to 
the glass container) is inserted into one of the closed ports. After the flask is firmly 
attached in its place, the valve is opened (the triangular notch is brought to point 
towards the insertion port) and the pressure within the glass container drops and 
equilibrates with the low pressure of the system. One can observe the pressure suddenly 
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rise when the unit is just attached and observe the slow dip in pressure as the pressure 
in the glass container is finally brought to equilibrium with the main system. The drying 
process will take anywhere between 2 – 4 days depending on how much water was 
used to re-suspend the nanotubes.  
 
A.3.  PEGylation of COOH-functionalized NTs:  
i) The NTs were resuspended in 25 mM MES (2-(N-morpholino)ethanesulfonic acid) 
buffer (pH 4.7) by making a 1 mg/mL solution and the solution was sonicated for 1-2 
hrs. The cut NTs should appear more soluble than the raw NTs.  
ii)  9.1 mg of sulfo-NHS (N-hydroxysulfosuccinimide) per mg of NT were added to the 
well-suspended NTs and sonicated for 5 min. 
iii) This was followed by the addition of 30.5 mg of (1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide) EDC per mg of NT and briefly sonicated. Then, a 
stir bar was added to the reaction mix and the reaction was vigorously stirred for ~20 
mins. This is the stage where the COOH groups are being activated for the attachment 
of biotin-PEG2000-amine groups.  
iv) In the meantime, a (>20mg/ml) concentrated solution of biotin-PEG2000-amine (20 
mg of BPA/mg of NT) was prepared in 100 mM phosphate buffer (pH 8.0), such that 
the volume of the BPA solution was the same as the NT solution in MES. This is so 
that the final pH is ~ 7.4-7.5 which would allow the reaction to go to completion. 
Increasing final pH is not recommended as this will cause the activated ester group to 
get quickly hydrolyzed and will prevent successful conjugation of BPA. The reaction 
was allowed to go to completion at RT for at least 3 hrs, or overnight at 4 °C.  
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v) After reaction completion, the solution was given a 3 min spin at 1000xg to remove 
any larger aggregates that should be discarded.  The supernatant was carefully collected 
and washed to remove the unreacted BPA. This was done by spinning the solution at 
504,000xg (70,000rpm) using the 70Ti fixed angle rotor in an ultracentrifuge for an hr. 
or until the PEG-NTs pellet. The supernatant will contain the excess free BPA. The 
supernatant was discarded carefully without disturbing the pellet and then the pellet 
was resuspended in fresh buffer (de-ionised water). The washes were repeated ~ 5 times 
so that the tubes are sufficiently washed.  
Note:   Make sure that the tubes that will be put in the ultracentrifuge rotors are precisely 
balanced upto +/- 10mg.  
vi) The pellet was collected and resuspended in sterile water. The PEG-NTs can be stored 
at 4°C. To calculate the yield, the absorbance of a dilute solution was taken at 808 nm 
such that the absorbance scales linearly. The A808nm can be multiplied by the dilution 
factor and then divided by 0.0465mg l-1 cm-1 (Extinction coefficient for SWNT) for 
calculating the NT concentration [2].  
Note:  Addition of biotin-PEG2000-amine helps in solubilizing the tubes further and the free 
biotin is useful for further conjugations. Besides, the toxicity of SWNTs has been 
shown to be dependent on their surface functionalization [2], [3]. PEG functionalization 
has shown to reduce the systemic toxicity of raw SWNTs [4]–[6]. The unreacted BPA 
must be separated from the NTs, else they will hamper with the conjugation steps ahead 





A.4. Conjugation of Streptavidin and HRP-biotin (test molecule): 
i) For 1 mg of biotin-PEG-NTs, large excesses (10 mg) of streptavidin was used to 
saturate the surface biotin on NTs. The 1 mg of biotin-PEG-nanotubes (at 200µg/ml) 
was mixed in small batches (200µL, added dropwise with intermittent mixing over 2-
3 mins) to a 2 mL solution of 5 mg/mL streptavidin (in PBS). This mixture was allowed 
to incubate on a shaking platform for ~ 30 mins. 
Note: This mixing must not be done all at once to avoid crosslinking and 
aggregation/clumping of NTs. The ideal case is where the NT-PEG is well covered 
with streptavidin, such that as many streptavidin sites are kept free as possible to allow 
maximum loading of HRP or HA.  
ii) The excess streptavidin was removed using a sucrose gradient of 4%, 10% and 30% 
w/v sucrose (or 4g, 10g and 30g respectively in 100mL) which was spun at 175,000xg 
or 32000rpm (using a swinging bucket SW32Ti rotor) in an ultracentrifuge. (Sucrose 
gradient preparation: The sucrose was layered from bottom to top; that is, 9 mL of the 
4% w/v sucrose solution was added first to the ultracentrifuge tube. This was followed 
by the addition of 9 mL of the 10% sucrose layer, under the 4% sucrose layer with the 
help of a syringe and long needle. Lastly, 9 mL of the 30% sucrose layer was added 
below the 10% sucrose layer with the help of the same long needle and syringe. Try to 
maintain a steady hand while layering the gradients to minimize mixing of two adjacent 
layers). The free streptavidin is held within the layers of the gradient, whereas the 
streptavidin coated NTs (strep-NT) form a pellet. This spin was allowed to go up to ~ 
18 hrs (less time could affect the yield, while more could allow the free streptavidin to 
settle along with the pelleted NTs) so that the nanotube yield of NT-Strep is ~ 50-60%. 
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It is essential that the sucrose solutions be removed carefully and discarded without 
disturbing the NT pellets – this can be done by carefully aspirating the sucrose solution 
from the top, all the way to the bottom of the gradient. If the pellet seems firm (which 
it usually does), the tube can be tilted to draw out the free sucrose solution. The pellet 
was re-suspended in 20 mM phosphate buffer (pH 7.4). Sonication in bursts, can be 
done to aid in the re-suspension, if necessary. The NT concentration can be calculated 
by taking the absorbance at 808 nm, which should be multiplied by the dilution factor 
and then divided by 0.0465mg l-1 cm-1 (Extinction coefficient for SWNT) [2]. 
iii) The strep-NT batch was split into two; to one batch (sample), biotinylated HRP 
(horseradish peroxidase – a test molecule here, to assess whether loading is possible) 
was mixed and to the other batch (control), a 2 mg/ml solution of biotin (at high excess 
of biotin, to block all the free sites of streptavidin) was added. The samples were kept 
on a rocking platform. After half an hour, biotinylated HRP was added to the second 
batch (control).  
iv) The sample and control batches were put through a sucrose gradient of 4%, 10% and 
30% w/v sucrose and spun at 32000 rpm in an ultracentrifuge to remove the excess 
HRP-biotin that can interfere with ELISAs for HRP. The NT-HRPs (sample) or the 
NT-BBs (biotin-blocked controls) were collected as a pellet. 
v) A TMB (3,3',5,5'-tetramethylbenzidine)-based ELISA was performed to assess loading 
of HRP onto NTs. For this ELISA, serial dilutions of both the sample and control were 
loaded onto 96 well, clear flat bottom plates. Each well had no more than 100 µL of 
solution. Similarly, serial dilutions (of known mass/concentrations of HRP) of HRP-
biotin (for the standard curve) were also loaded onto the plate. To these wells, 100 µL 
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of TMB solution was added and the absorbance was taken in a plate reader at 652nm. 
If HRP is present, it would give a blue coloration with TMB. The amount of HRP in 
the sample and control could be estimated from the plotted standard curve.  
 
A.5. Insect culture – Expression of hemagglutinin (antigen) [7]:  
The cell lines used, SF9 and High Five, were maintained as suspension culture for all 
passages. When animating frozen cell stocks, the cell count might be too low to begin 
with suspension culture – so it is better to begin them as adherent culture initially (if 
there are ~ 1 – 3 million viable cells in the thawed stock) and then switch over to 
suspension culture when the viable cell count is high enough (more than 9 million 
viable cells). Maintaining insect cells as suspension culture proves to be relatively 
easier because adherent culture need to be dislodged from the flasks by tapping the 
sides (for every passage) – which introduces a lot of shear to the cells and can cause 
cell death.  
Remember to maintain sterile conditions for all cell culture techniques. Signs of 
contamination: Declining cell health or if cell viability is severely hampered in 
successive passages, either the passage number is too high (i.e. not to exceed passage 
no. 25, or maintain the same culture for more than 3 months) or the culture could be 
contaminated. It is a good idea to start a fresh pass from a frozen cell stock during such 
an instance. Sometimes, contamination can be visualized on a microscope using Trypan 
Blue stain – the background might appear ‘grainy’ (as opposed to a clear background, 
when the cells are not contaminated) or you might be able to see smaller cells on the 
same slide along with the insect cells. Fungal contamination could show up as a small 
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but visible “floating, fuzzy ball” in suspension culture or will grow to form a “little 
colorful island” on top of adherent culture. Contamination can also appear to make the 
cell suspension excessively turbid – more than you would normally see. A color change 
in the media is also visible at times.  
All mutants of hemagglutinin (HT, TT, chimeras) were expressed using the following 
protocol:  
i) The baculoviral transfer plasmid was transformed into DH10Bac bacteria, which were 
midiprepped (PureLink® Genomic DNA Kits, Thermo Fisher Scientific) to yield 
bacmids.  
ii) SF9 cells were seeded in 6-well plates at a density of 2 x 105 cells/cm2. The bacmids 
were transfected into SF9 cells using Cellfectin II transfection reagent. For this, 2µg of 
the bacmid was diluted in serum free TNM-FH (with 1% Pen-Strep and 0.1% Pluronic 
F68) and mixed with 6µL of Cellfectin II. This was mixed and allowed to incubate for 
20 mins at room temperature.  
iii) The SF9 cells would have stuck to the bottom of the plate by this point. The supernatant 
of the seeded SF9 cells was removed and replaced with 2 mL serum free TNM-FH. 
The bacmid-reagent complex was added to this mix, and the plate was gently agitated 
for 5 mins to facilitate mixing. The media was changed after 6 hours to 2 mL of full 
TNM-FH (10% FBS, 1% Pen-Strep and 0.1% Pluronic F68). The plate was incubated 
at 28ºC without CO2 for 6 days, and was occasionally checked to observe signs of 
infection (cells appear larger, enlarged nuclei, easily detach from the plate).   
80 
 
iv) The media was harvested after 6 days (centrifugation at 2000xg, 5mins) and this 
contained the “P1” or the initial baculoviral stock. Such a stock of baculoviruses can 
be stored at 4ºC.  
v) This P1 stock was used to generate subsequent ‘amplified’ baculoviral stocks. The SF9 
cells were seeded in large T175 flasks at a density of 2 x 105 cells/cm2, by allowing 
them to settle for 20 min and subsequently replacing the media with 50 mL TNM-FH 
with reduced serum (3% FBS). To this, 400 µL of P1 was added, and the flask was 
swirled to allow even distribution of the baculoviral inoculum. The flask was incubated 
at 28ºC without CO2 for 6 days, while occasionally checking for signs of infection.  
vi) The media was harvested by centrifugation at 2000xg for 5 min to yield the “P2” stock. 
The baculoviruses could be amplified as required and be used for expression.  
vii) Hemagglutinin expression: For a 50mL expression, ~ 25 – 30 million High Five cells 
were harvested from a pass (centrifugation at 100xg for 7 mins). These cells were re-
suspended with 4.5 mL of baculoviral stock of P3 and the cell suspension was incubated 
at room temperature for 20 min. In the meantime, 46 mL of fresh SFX medium was 
placed into a disposable 125 mL Erlenmeyer flask and 500 µL of a 6 mM stock solution 
of biotin (stock solution made in DI water, sterile filtered, with the minimum amount 
– a few drops – of 10N NaOH to enhance solubility of biotin) was added to this flask 
(final biotin concentration was 50 µM). 
Note:  Swirl-mix media with biotin well before adding cells to media, to ensure that the pH is 
uniform throughout.  
Note: Always test well-in-advance (before beginning expression) that the pH of the biotin 
stock does not alter the pH of the insect media. For this: Mix the 500 µL of a 6 mM 
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stock solution of biotin solution to 46 mL of SFX media and compare the pH of this 
mixture vs. that of the SFX media without the biotin solution added. The pH would 
have barely changed at all. This is a crucial step as the pH of the media is close to the 
pI of hemagglutinin (pI ~ 6.4) and increasing the pH of the media could possibly cause 
loss of protein due to precipitation at the pI. 
viii) After the 20-minute incubation, the cell suspension was added to the SFX media, mixed 
well, and incubated at 28ºC without CO2 for 72 – 96 hrs.  
ix) The media was harvested by centrifuging the suspension at 2000xg for 10 min. The 
supernatant contains the hemagglutinin since the plasmid had a signal peptide to trigger 
secretion into the media. Hemagglutinin was purified using Ni-NTA resin. 
 
*** Alternate method of Insect cell transfection using transfection reagent: 
HA expression was also attempted using two transfection agents (i.e. without the use 
of baculoviruses): 1. Gene Juice (EMD Millipore) 2. XtremeGene HP (Sigma). HA 
could not be expressed with Genejuice, even after trying to optimize expression 
conditions. XtremeGene HP was successfully used to express hemagglutinin (wt.  HA, 
HT HA and TT HA) using SF9 cells. High Five cells gave a relatively lower yield when 
paired with this transfection reagent.  The transfection protocol used for Xtremegene 
HP is as recommended by Sigma. The following protocol has been modified from their 
suggested protocol from their product info sheet available online:  
i) X-tremeGENE HP DNA Transfection Reagent, DNA and diluent (BacVector media, 
EMD Millipore, serum free) was allowed to equilibrate to +15 to +25°C. The X-
tremeGENE HP DNA Transfection Reagent vial was briefly vortexed.  
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ii)  The DNA was diluted with appropriate diluent (e.g., serum-free medium) to a final 
concentration of 1 µg plasmid DNA /100 µL medium (0.01 µg/µL) and gently mixed. 
(Use a minimum of 100 µl of diluent; lower volumes may significantly decrease 
transfection efficiency) 
iii) 3 µL of the X-tremeGENE HP DNA Transfection Reagent per µg of DNA (3:1 = µL 
reagent: µg DNA was used, but other ratios such as 2: 1 or 4:1 could also be attempted) 
was pipetted directly into the medium containing the diluted DNA without coming into 
contact with the walls of the plastic tubes and gently mixed. (To avoid adversely 
affecting transfection efficiency, do not allow undiluted X-tremeGENE HP DNA 
Transfection Reagent to come into contact with plastic surfaces. Do not use siliconized 
pipette tips or tubes.)  
iv)  The transfection reagent: DNA complex was incubated for 20 minutes at +15 to 
+25°C. (Some reagent: DNA ratios and cell types may require longer incubation (15 - 
30 min). Determine this for your particular cell line and the ratio used.)  
v) In the meantime, SF9 cells were seeded at a density of 1 x 106 cells/mL in fresh 
BacVector media (serum free, EMD Millipore). The transfection complex was added 
to the cells in a dropwise manner. The wells or flasks were gently swirled during the 
addition of the complex to ensure even distribution throughout the suspension. (Once 
the transfection reagent: DNA complex has been added to the cells, there is no need to 
replace with fresh medium - as may be necessary with other transfection reagents) 
vi)  Following transfection, the cells were incubated for 18 – 72 hours before measuring 
protein expression. The duration of incubation will depend on many factors, including 
the transfected vector construct, the cell type being transfected, the cell medium, cell 
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density, and the type of protein being expressed. After the incubation period, the 
proteins were purified using the Ni-NTA resin.  
 
A.6. Protein Purification: 
Hemagglutinin has a His tag at the C- terminus, which was used to purify it by affinity 
chromatography using a Ni column/resin. This step was followed by size exclusion 
chromatography to separate the trimer fraction (desired) from larger protein aggregates.  
i) A fresh Ni Agarose column must be used per protein. The column was washed with 
plenty of water to remove the 20% alcohol storage buffer and equilibrated with ~ 5 
column volumes of equilibration buffer (chilled PBS, pH 8.0). 
ii) The media supernatant was incubated with the Ni resin for 2-4 hours at 4ºC on a rocking 
platform, after which the mixture was poured through an empty column and the resin 
was allowed to settle in it while the supernatant flowed through.  
iii) The column was washed with copious amounts of wash buffer (15mL x 4 times) (50 
mM Na2HCO3, 300 mM NaCl, 20 mM imidazole, pH 8) after which the bottom of the 
column was capped with a stopper.  
Note:  The pH of the buffer for washes/elution and all further handling is best maintained at 
8.0 and not below 8.0. The pI of hemagglutinin ~ 6.4. Below pH 6, HA tends to undergo 
conformational change. Physiological pH can also promote aggregation. Swartz et al. 
(PNAS, 2014) found that basic pH are better to minimize aggregation (they recommend 
working closer to pH 10). 
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iv) 3 mL of elution buffer (50 mM Na2HCO3, 300 mM NaCl, 300 mM imidazole, pH 8) 
was added to the column and allowed to incubate for 5 min, after which it was collected. 
This was repeated three times to collect a total of three fractions.  
v) Spin filter prep: In the meantime, a spin filter was washed with copious amounts of de-
ionized water and chilled PBS was added to it, and was spun at 3000xg for 20 min at 
4ºC. This can help minimize the amount of protein that non-specifically sticks to the 
filter.  
vi) The fractions were pooled, aside from keeping 20 µL of each for characterization by 
SDS PAGE, and the volume was made up to 15 mL, after which it was concentrated 
using the ‘prepared’ spin filter down to ~ 1 – 1.5 mL. The filtrate was discarded while 
fresh chilled PBS was added to the retentate to make up the volume to 15 mL and the 
spin was repeated  this is the “first wash” to lower the imidazole concentrations in 
the buffer. This wash was repeated twice with chilled PBS (spun at 3000xg for 20 min 
at 4ºC). The final concentrated volume with HA was brought down between 800 µL – 
1 mL which was injected into the SEC system (saving ~ 20 µL for an SDS PAGE gel).  
vii) This concentrate was passed through a size exclusion chromatography (SEC, AKTA, 
Superdex 200 10/300 GL increase). The trimer eluted at ~ 9 mL whereas the aggregate 
eluted at ~12 mL.  
***  The “trimer” fraction collected after SEC should be handled very carefully. Store at 4 ͦC 
or chilled conditions continually. Even when holding the fraction in your hand while 
carrying it from bench to bench try to maintain chilled conditions. If one has to quickly 
bring it from one point to another – say, AKTA to the fridge/other storage unit: try not 
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to hold the Eppendorf tube firmly within your palm as that could raise the temperature. 
Hold the tube on the very top.  
****  While running the SEC, always try to end up collecting most of the trimer within one 
fraction.  This is important because, HA has to be as concentrated as possible in that 
single eluted fraction as is. Concentration at this stage is strongly discouraged, as it is 
observed to promote aggregation.   
****   It would be ideal to do the conjugations onto Streptavidin coated nanotubes the very 
same day as when the SEC is completed. This will prevent the HA from possibly 
aggregating by letting it sit overnight (even if stored at 4 ͦC). The HA yield was 
quantified (and compared) by running an SDS PAGE gel on the imidazole fractions, 
the concentrated fraction and the SEC fractions and comparing their intensity to that of 
varying concentrations of BSA.  
****  To quicken the SDS PAGE staining procedure, the dye can be mixed with the gel and 
microwaved for 30 s  this will reduce the incubation time from 1 h to 15 min. The 
same trick can be used to quicken de-staining as well.  
 
A.7. Conjugation of HA, followed by Western blots: 
i) The steps outlined in section 2.2.3 were repeated to make more strep-NTs. This strep-
NT batch was split into two; to each batch of 500 µg of streptavidin-NTs, 750 µg of 
HA (head biotinylated or tail biotinylated) was mixed. This mixture was allowed to 
incubate for 45 min – 1hr. The biotinylated HA (HT or TT) was expressed and purified 
as mentioned in sections 2.2.5 and 2.2.6. The excess/free HA was removed using a 
sucrose gradient of 4%, 10% and 30% sucrose by spinning at 175,000xg in an 
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ultracentrifuge for ~ 15.5 – 16 h (increasing spin time can cause free HA to settle along 
with the NT pellet). It is essential that the sucrose solutions be removed carefully and 
discarded without disturbing the NT pellets – this can be done by carefully aspirating 
the sucrose solution from the top, all the way to the bottom of the gradient. If the pellet 
seems firm (which it usually does), the tube can be tilted to draw out the free sucrose 
solution. The pellet was re-suspended in 20mM phosphate buffer (pH 7.4). Again, the 
nanotube concentration of HA-NT was calculated by repeating the above procedure of 
taking the absorbance at 808 nm and repeating above-mentioned calculations.  
ii) A western blot was performed to estimate loading of HA onto NT: a range of known 
amounts of HA-NT was taken (in terms of weight of NTs in ~100s of ng). Also, varying 
known amounts of HA alone were also used (these served as standards to help estimate 
the amount of HA loaded onto NTs). All samples were boiled in SDS at 80 ºC in a PCR 
machine for ~ 30-40 min after which they were characterized by gel electrophoresis. 
The proteins in the samples entered the gels, while the nanotubes remained in the wells 
itself. The proteins were transferred from the gels onto nitrocellulose membranes (for 
the western blot) and blocked in 5% BSA solution using a blot transfer apparatus. The 
primary antibody (1:2000 dilution in 1% BSA solution) used for the blot was an 
influenza HA anti-head antibody (PY102) obtained from our collaborators from the 
Icahn School of Medicine at Mount Sinai. The secondary antibody used was an anti-
mouse goat HRP-conjugated IgG (1:10,000 dilution in 1% BSA solution). The relative 
densities of the bands were estimated using the ImageJ software and plotting the linear 
range of HA standards loaded onto gels. Once we estimated the ng amounts of loaded 
87 
 
HA, we could calculate the loading by dividing the HA amount (ng) by the NT amount 
(ng) loaded per well on the gels.  
 
A.8. Addition of Adjuvants and dilutions before vaccination: 
The HA-NTs (HT-NT and TT-NT) were diluted to make aliquots such that there would 
be sufficient HA loaded onto the tubes for each mouse to receive 5 µg of HA. The 
volume injected per mouse per round of injection was 50 µL, out of which 45 µL was 
the vaccine and 5µL was the adjuvant, poly I:C. A quick vortexing before and after 
poly I:C addition was helpful in ensuring proper mixing. 
 
Note:  Apart from the conjugates with HA oriented in two ways, a required control required 
for the in-vivo testing of a vaccine is the “vehicle-only” control which should ideally 
lack the antigen or in our case, HA. The aim here is to show that the vehicle alone does 
not trigger the broadly neutralizing response. I decided to use PEG-NTs at this stage 
and not Strep-NTs for the “vehicle-only” control.  Streptavidin being ‘more accessible’ 
to the immune system in the case of the Strep-NTs might not make for an appropriate 
control because the streptavidin in the case of the HA-NT conjugates would be within 
the ‘inner layers’ i.e. sandwiched between PEG on one side and HA on the other and 
closely stacked together on NTs; therefore, streptavidin would not be as easily “seen” 






A.9. In-vivo cH5/1N1 challenge: 
The immunizations and viral challenge experiments were carried out by our 
collaborators at the Icahn School of Medicine at Mount Sinai. For each type of sample 
(whether HT-NT, TT-NT, or NT-PEG ‘vehicle-only’ control) five mice were 
vaccinated, which yields a total of fifteen vaccinated mice. The HA-NT conjugates was 
administered twice, as one prime and one boost, to BALB/c mice, with a gap of 3 to 4-
weeks. After both rounds of vaccination, blood samples were collected for ELISAs to 
assess anti-stalk antibody titers. 
 After the second round of vaccination, another 4 weeks were allowed to pass after 
which the mice were challenged with a ‘cH5/1N1’ virus. CH5/1N1 is a chimeric virus, 
modified to have the same stalk region as that of H1 hemagglutinin, but a different HA 
head region (belonging to H5 subtype). After the challenge, the mice were monitored 
for the loss in their body weight; if the loss exceeded more than 25% of their body 
weight, they were euthanized. 
 
A.10. Protein Expression (Hemagglutinin binding proteins): 
i) The plasmid (pET 28b (+)) containing the HB protein sequence was transformed into 
the NiCo21(DE3) cell line (catalog# C2529H) according to the protocol suggested on 
the NEB (New England BioLabs) website.  
ii) After transformation, the bacteria was allowed to grow in SOC (super optimal broth) 
media (without antibiotic) for 1 hr at 37ºC. 500µL of this culture was used to inoculate 
a fresh 5 mL pre-autoclaved LB (Luria Bertani) media stock (with antibiotic: 
kanamycin) near a flame, and was incubated at 37 ºC with shaking, overnight.  
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iii) 1L LB media was prepared that evening (by dissolving 25g of LB media powder in 1L 
culture flasks with distilled water). The media was autoclaved and set aside.  
iv) Scale up: The following morning, 1 mL of antibiotic (kanamycin) was added to the 
scaled-up media near a flame, to maintain sterile conditions. Subsequently, 1 mL of 
inoculum (that was left overnight at 37ºC) was added to the 1L flask.  
v) The flask was placed in a shaker incubator and left at 37ºC for 4 to 5 h. This is when 
the bacteria are allowed to grow until they reach logarithmic phase.  
vi) 400 µM of freshly prepared IPTG solution was added per liter of inoculated media. The 
temperature of the shaker incubator was reduced to 16ºC, and was incubated overnight.  
vii) The next day, the cells were pelleted by spinning at 6000xg for 1 h, while the 
supernatant was discarded.  
viii) The pellets were made to undergo repeated freeze-thaw cycles first to lyse cells. 50 mL 
of lysis buffer (50 mM Phosphate, 500 mM NaCl, 25 mM imidazole, 0.2 mg/ml 
DNAse, 1 mM PMSF, pH 8.0) was added to a 1g pellet.   
Note: In place of PMSF, we have more recently started using SIGMA’s protease cocktail 
inhibitor tablets (EDTA free – to make it compatible with the Ni-NTA resin) – as it 
offers a wider range of types of protease inhibitors. For these, one tablet was dissolved 
in 100mL of lysis buffer.  
i) The pellet was homogenized in the lysis buffer and then sonicated (to completely lyse 
cells) for 5 minutes in an ice bath to ensure that proteins do not get denatured due to 
over-heating. Sonication parameters: 3 s ON and 3 s OFF, 20% amplitude, 4-5mins. 
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ix) After cell lysis, the cell debris was spun down at 20,000xg for 1h (or 30,000xg for 30 
mins). The supernatant (contains the proteins) was collected. The pellet should be 
discarded only if the protein is not expected to be present in inclusion bodies.  
 
A.11. Protein Purification: 
The proteins being expressed have a His tag on either the N- or C- terminus, which can 
be used to purify them using a Ni column/resin using the principle of affinity 
chromatography.  
i) A fresh Ni Agarose column must be used per protein. The column was washed with 
plenty of water to remove the 20% alcohol storage buffer and equilibrated with ~ 5 
column volumes of equilibration buffer (50 mM Phosphate, 500 mM NaCl, 25 mM 
imidazole, pH 8.0). 
Note:   A high NaCl concentration was maintained i.e. 500mM to minimize non-specific 
adsorption of irrelevant proteins onto the Ni-NTA resin.   
ii) The lysate was passed through the column, while the flow through was collected.  
iii) The column was washed once again with ~ 3 column volumes of equilibration buffer.  
iv) 10 column volume washes were performed with 50 mM and 100 mM imidazole 
buffers, pH 8.0. All washes were collected. The 100 mM wash was collected as 
fractions.  
v) Finally, the protein was eluted with 10 column volumes of 400 mM imidazole wash, 
while collecting fractions.  
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vi) Gels were run on the fractions to assess which fraction had the protein of interest with 
desired purity. The absorbance at 280 nm was taken to determine the protein 
concentration.   
 
A.12. Bacterial Protein Expression (protein with unnatural amino acid p-Azido 
phenylalanine F*): 
ii) The plasmid (pET 28b (+)) containing the Leukotoxin E-F* was co-transformed along 
with the pEVOL vector (Addgene reference: pEvol-pAzFRS.2.t1 (Plasmid #73546); 
chloramphenicol resistance) into the NiCo21 (DE3) cell line (catalog# C2529H) 
according to the protocol suggested on the NEB (New England BioLabs) website.  
iii) After transformation, the bacteria were allowed to grow in SOC (super optimal broth) 
media (without antibiotic) for 1 h at 37 ºC. 500µL of this culture was used to inoculate 
a fresh 5mL pre-autoclaved LB (Luria Bertani) media stock (with antibiotic: 
kanamycin) near a flame, and was incubated at 37 ºC with shaking, overnight.  
iv) 1L LB media was prepared that evening (by dissolving 25g of LB media powder in 1L 
culture flasks with distilled water). The media was autoclaved and set aside.  
v) Scale up: The following morning, 1 mL of antibiotic (kanamycin) was added to the 
scaled-up media near a flame, to maintain sterile conditions. Subsequently, 1 mL of 
inoculum (that was left overnight at 37ºC) was added to the 1L flask.  
vi) The flask was placed in a shaker incubator and left at 37ºC for 4 to 5 hours. This is 
when the bacteria are allowed to grow until it reaches logarithmic phase.  
vii) 400 µM of freshly prepared IPTG solution, 0.02% w/v of arabinose and 1 mM of p-
azido phenylalanine (dissolved initially in DMSO to facilitate dissolution and 
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subsequently added to culture) were added per liter of inoculated media after which the 
temperature of the shaker incubator was reduced to 16ºC, and the culture was allowed 
to incubate overnight.  
viii) The following day, the cells were pelleted by spinning at 6000xg for 30 mins - 1 h, 
while the supernatant was discarded.  
ix) The pellets were made to undergo repeated freeze-thaw cycles first to lyse cells. 50mL 
of lysis buffer (50 mM Phosphate, 500 mM NaCl, 25 mM imidazole, 0.2 mg/ml 
DNAse, 1mM PMSF, pH 8.0) was added to a 1g pellet.  
 Note: In place of PMSF, we have more recently started using SIGMA’s protease cocktail 
inhibitor tablets (EDTA free – to make it compatible with the Ni-NTA resin) – as it 
offers a wider range of types of protease inhibitors. For these, one tablet was dissolved 
in 100mL of lysis buffer.  
x) The pellet was homogenized in the lysis buffer and then sonicated (to completely lyse 
cells) for 5 minutes in an ice bath to ensure that proteins do not get denatured due to 
over-heating. Sonication parameters: 3 s ON and 3 s OFF, 20% amplitude, 4-5mins. 
xi) After cell lysis, the cell debris was spun down at 20,000xg for 1h. The supernatant 
(contains the proteins) was collected. The pellet should be discarded only if the protein 
is not expected to be present in inclusion bodies.  







A.13. Mammalian culture – Protein expression: 
Antibody fragments were expressed using mammalian cells, more specifically 293F 
cells. These cells were grown in suspension culture (in Expi293 media) and seeded at 
a density of 3x105 to 5x105 cells/mL for each pass to maintain the cell line.  
Note:   All cell culture was done in strictly aseptic conditions, in a BSL-2 cabinet. 
The protocol for transfection has been taken from the literature for the product sold by 
Thermo Fisher Scientific called ExpiFectamine 293. The protocol has been re-iterated 
below for the sake of clarity.  Also, mammalian suspension cell culture was performed 
in disposable 125mL Erlenmeyer flasks.  
 
i) The transfections were done in batches of 30 mL. For each transfection/batch, on the 
day before the transfections were carried out: 60 million cells were seeded in 30 mL of 
Expi293 serum-free media (or at a density of 2x106 cells/mL) and incubated at 37°C in 
a humidified atmosphere of 8% CO2 in air on an orbital shaker rotating at 125 rpm. 
The viability must be above 95% for effective transfection and protein yields. 
ii) After 24 hours, the cell count/viability was assessed with Trypan blue stain.  
iii) For each transfection, 75 million cells were seeded in 25.5 mL of Expi293 media (the 
volume was made up to 25.5 mL with fresh media) in a 125 mL Erlenmeyer flask.   
iv) The DNA-transfection reagent complexes were made as follows:  
a. 30µg of plasmid DNA was diluted using OPTI-MEM reduced serum media (Cat. 
no. 31985-062) to a final volume of 1.5 mL. 
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b. 81 µL of transfection reagent was diluted using OPTI-MEM media to a volume of 
1.5mL and was incubated for 5 minutes. Increasing the incubation time reduces 
transfection efficiency. 
c. The diluted DNA was added to the diluted transfection reagent to a final volume of 
3mL and mixed gently. This solution was incubated at room temperature for 20-30 
mins. This allows the DNA to form complexes with the transfection reagent.  
v) The DNA-transfection reagent was added to the seeded flask and mixed gently. This 
was incubated at 37°C in a humidified atmosphere of 8% CO2 in air on an orbital 
shaker rotating at 125 rpm. 
vi) After 16-18 h, 150 μL of ExpiFectamine™ 293 Transfection Enhancer 1 and 1.5 mL 
of ExpiFectamine™ 293 Transfection Enhancer 2 was added to the flask and returned 
to the incubator for 6-7 days.  
vii) Since the antibodies were secreted into the media, the media was harvested and proteins 
were purified using the Ni-NTA agarose resin as specified in section A.11. It is crucial 
to note that the Expi293 media is not compatible with the Ni resin as it contains agents 
that could leach Ni off the resin, therefore the media supernatant must be buffer 
exchanged with PBS before loading onto the column.  
 
A.14. Activity testing using Fluorescence Activated Cell Sorting: 
i) 100,000 cells (either CCR5+ 293T cells or control 293T cells) were plated per well in 
a 96-well plate (25µL of a cell suspension at 4 x (10)6).  
Note:  Make sure to save some cells (both CCR5+ and the control 293T) for optimizing the 
gate selection and voltage on the Cell Sorter. 
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ii) 50µL of known concentration of inhibitor was added to the cells and was incubated at 
room temperature for 30 minutes.  
iii) This was followed by the addition of 25µL containing 10 nanomoles of FLSC (Full 
Length Single Chain) to each well and was incubated at 4ºC for 30 minutes.  
Note:  FLSC is a fusion protein consisting of the HIV’s envelope glycoprotein gp120 and the 
human CD4; along with a human Fc region (for detection) [8], [9].  FLSC interacts 
with CCR5 at similar sites as HIV; at the N terminus and the Extra Cellular Loop 2 
(ECL2). 
iv) The cells in the plate were spun at 400xg for 4 minutes, and the supernatant was 
discarded by gently emptying contents into a sink and tapping the plate dry on a paper 
towel (carefully to not dislodge the cells by tapping too hard). The cells were re-
suspended with 100µL PBS. 
v) Step iv was repeated for a wash and the cells were re-suspended in 100 µL of PBS. The 
plate is ready to be run on the Cell Sorter (run on High Throughput Screening 
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